## Optimal dosing of anti-cancer treatment under drug-induced plasticity

Einar Bjarki Gunnarsson<sup>1,2</sup> Benedikt Vilji Magnússon<sup>1</sup> Jasmine Foo<sup>2</sup>

<sup>1</sup>Division of Applied Mathematics and Statistics, Science Institute, University of Iceland <sup>2</sup>School of Mathematics, University of Minnesota

#### Abstract

While cancer has traditionally been considered a genetic disease, mounting evidence indicates an important role for non-genetic (epigenetic) mechanisms. Common anti-cancer drugs have recently been observed to induce the adoption of reversible drug-tolerant cell states, thereby accelerating the evolution of drug resistance. Determining how to optimally balance the competing goals of killing the tumor bulk and delaying resistance evolution in this scenario is a nontrivial question of high clinical importance. In this work, we use a combined mathematical and computational approach to study optimal dosing of anti-cancer drug treatment under drug-induced cell plasticity. Our results show that the optimal treatment steers the tumor into a fixed equilibrium composition while balancing the trade-off between cell kill and tolerance induction in a precisely quantifiable way. Under linear induction of tolerance, a low-dose constant strategy is optimal in equilibrium, while under uniform induction of tolerance, alternating between a large dose and no dose is best. The directionality of drug induction, whether the drug elevates transitions from sensitivity to tolerance or inhibits transitions back, significantly affects optimal dosing. To demonstrate the applicability of our approach, we use it to identify an optimal low-dose strategy for colorectal cancer using publicly available in vitro data.

## 1 Introduction

Cancer is the result of a complex evolutionary process which results in cells gaining the ability to divide uncontrollably [1, 2]. While genetic mutations have long been understood to be important drivers of cancer evolution, it has more recently become clear that epigenetic mechanisms such as methylation and acetylation are sufficient to fulfill the traditional hallmarks of cancer [3, 4, 5, 6]. Epigenetic mechanisms are both heritable and reversible, and they can enable cells to switch dynamically between two or more phenotypic states, which commonly show differential responses to drug treatment. In fact, tumor cells in many cancer types have been observed to adopt reversible drug-tolerant or stem-like states *in vitro*, which enables the tumor to temporarily evade drug treatment and sets the stage for the evolution of more permanent resistance mechanisms [7, 8, 9, 10, 11, 12, 13, 14]. While these drug-tolerant states can exist independently of treatment [7, 15, 11], recent evidence indicates that common anti-cancer drugs can also induce or accelerate their adoption, a phenomenon we refer to as *drug-induced plasticity* [15, 8, 11, 16, 12, 17, 18]. Drug induction is already well known in the context of genetic mutations, where both anti-cancer and anti-bacterial drugs have been observed to cause genomic instability or *mutagenesis*, referring to an elevated mutation rate occurring as a result of the stress imposed by the treatment [19, 20, 21, 22, 23].

Anti-cancer drug treatment has traditionally been administered under the "maximum tolerated dose" (MTD) paradigm, where the goal is to eradicate the tumor as quickly as possible and minimize the probability of spontaneous resistance-conferring mutations [24, 25, 26]. Non-genetic cell plasticity fundamentally confounds the reasoning behind this strategy, especially if it is induced by the drug. First, if drug-tolerant states are adopted independently of the drug, it is likely that drug-tolerant cells will preexist treatment in large numbers, even if they form only a small fraction of the tumor bulk [5]. In addition, since non-genetic mechanisms usually operate much faster than genetic mutations [5, 4, 27], a non-negligible fraction of drug-sensitive cells will adopt drug tolerance under treatment. This means that it can be impossible to kill the tumor, no matter how large a dose is applied [14]. Second, if the drug induces tolerance adoption in a dose-dependent manner, applying larger doses with the aim of maximizing cell kill has the downside of promoting resistance evolution. This trade-off has been explored in several recent mathematical modeling works, which generally find that continuous low-dose or intermittent strategies outperform MTD treatment [28, 29, 30, 31, 32, 33]. However, these works usually focus on one potential model of drug-induced tolerance and some only consider the case of irreversible genetic resistance. In addition, many of these works only consider constant or intermittent strategies. Overall, there is a lack of generalized insights into how different potential forms of drug-induced tolerance influence optimal treatment decisions.

In this work, we seek a more systematic understanding of optimal dosing strategies under drug-induced cell plasticity. We seek both a qualitative understanding of the characteristics of optimal strategies and simple quantitative methods for computing them. We consider many different possible forms of drug-induced tolerance and explore how and why different forms lead to different optimal strategies. Our work differs from previous work in several important ways. First, whereas prior work generally assumes that tolerance is induced through elevated transitions from drug-sensitivity to drug-tolerance, it is also biologically plausible that the drug inhibits transitions from tolerance back to sensitivity, or that it affects both transitions simultaneously. For example, hypermethylation in the promoter regions of tumor suppressor genes has been associated with gene silencing and drug resistance in many cancers [1, 4, 34, 35, 36]. When a cell divides, existing methylation patterns are preserved by the maintence methyltransferase DNMT1, while *de novo* methylation is carried out by the methyltransferases DNMT3A/3B [37, 38, 39]. If a drug-tolerant state is conferred via methylation, drug-induced upregulation of DNMT3A/3B will induce the adoption of the tolerant state, while drug-induced upregulation of DNMT1 will inhibit transitions out of it. The notion that the drug may not only elevate transitions from sensitivity to tolerance is further supported by experimental evidence indicating that the drug can influence all possible phenotypic transitions simultaneously [8, 12, 17]. Second, whereas many prominent prior works assume that the level of tolerance induction is linear as a function of the drug dose, we also consider the case where tolerance is induced uniformly in the presence of drug. These two forms of drug-induced tolerance were observed in a recent experimental work by Russo et al. [18], and they emerge as limiting cases of a more general Michaelis-Menten form of tolerance induction as is discussed in Section 4.3. Third, while most previous work is computational in nature, we establish mathematical results which provide general insights that apply across all biologically relevant parameter regimes. Finally, whereas some previous



Figure 1: Mathematical model of drug-induced tolerance. (a) In the mathematical model, cells transition between two states, a drug-sensitive (type-0) state and a drug-tolerant (type-1) state. Cells in state 0 divide at rate  $b_0$ , die at rate  $d_0$  and transition to state 1 at rate  $\mu$ . Cells in state 1 divide at rate  $b_1$ , die at rate  $d_1$  and transition to state 0 at rate  $\nu$ . The sensitive cell death rate  $d_0$  and the transition rates  $\mu$  and  $\nu$  depend on the drug dose c. (b) The sensitive cell death rate follows a Michaelis-Menten equation of the form  $d_0(c) = d_0 + (d_{\max} - d_0)c/(c+1)$ , where  $d_0$  is the death rate in the absence of drug and  $d_{\max}$  is the saturation death rate under an arbitrarily large drug dose. The dose c is normalized to the EC<sub>50</sub> dose for  $d_0$ , meaning that the drug has half the maximal effect at dose c = 1. (c) The transition rate  $\mu(c)$  from drug-sensitivity to drug-tolerance is assumed either a linearly increasing function of c or to be uniformly elevated in the presence of drug. These two forms of drug-induced tolerance were observed in a recent study by Russo et al. [18] and they also emerge as limiting cases of more general Michaelis-Menten dynamics (Section 4.3). (d) The transition rate  $\nu(c)$  from drug-tolerance to drug-sensitivity is similarly assumed either a linearly decreasing function of c or uniformly inhibited in the presence of drug.

works focus on irreversible transitions from drug-sensitivity to drug-resistance, we study the case of reversible phenotypic switching between sensitivity and tolerance. We compare and contrast our results with previous work in more detail in the discussion section.

## 2 Results

In our investigation, we employ a mathematical model involving transitions between two cell states, a drug-sensitive state (type-0) and a drug-tolerant state (type-1) (Section 4.1). The death rate  $d_0(c)$  of sensitive cells, the transition rate  $\mu(c)$  from sensitivity to tolerance, and the transition rate  $\nu(c)$  from tolerance to sensitivity, are assumed to depend on the drug dose c, modeling drug-induced tolerance. We consider two different forms for  $\mu(c)$  and  $\nu(c)$ depending on whether we are studying linear or uniform induction of tolerance (Figure 1).

## 2.1 Optimal dosing under linear induction of tolerance

We begin by investigating optimal dosing strategies under linear induction of tolerance  $(\mu(c) = \mu_0 + kc \text{ and } \nu(c) = \nu_0 - mc$  for  $k, m \ge 0$ ). The treatment goal is to minimize the total tumor burden at the end of a treatment horizon [0, T] (Section 4.6). To compute optimal dosing strategies, we implemented the so-called forward-backward sweep method in MATLAB (Section S1.1). All codes necessary to reproduce the figures in this study and to compute optimal strategies for new user-defined parameter settings are available at https://github.com/egunnars/optimal\_dosing\_drug-induced\_plasticity.

To determine the optimal strategy, we allow the drug dose to change with time, c(t). It is worth noting that under a constant dose c(t) = c, the model dynamics simplify, and the tumor eventually grows (or decays) exponentially at a fixed rate  $\sigma(c)$  given by

$$\sigma(c) = \frac{1}{2} \Big( \lambda_0(c) - \mu(c) + \lambda_1 - \nu(c) + \sqrt{(\lambda_0(c) - \mu(c) - \lambda_1 + \nu(c))^2 + 4\mu(c)\nu(c)} \Big), \quad (1)$$

Here,  $\lambda_0(c) = b_0 - d_0(c)$  is the net division rate of the sensitive cells and  $\lambda_1 = b_1 - d_1$  is the net division rate of the tolerant cells (Section 4.1). Moreover, the intratumor composition eventually reaches an equilibrium, where the proportion of sensitive cells in the population becomes the constant  $\bar{f}_0(c)$  given by

$$\bar{f}_0(c) = \frac{\nu(c)}{\sigma(c) - \lambda_0(c) + \mu(c) + \nu(c)}.$$
(2)

Thus, under a constant dose c, it is possible to maintain the tumor at a stable intratumor composition which leads to a fixed exponential growth rate  $\sigma(c)$  (Section 4.5).

In what follows, we will consider three cases separately, depending on which transitions are affected by the drug. In Case I, the drug only increases the transition rate from sensitivity to tolerance (k > 0, m = 0), in Case II, the drug only decreases the transition rate from tolerance to sensitivity (k = 0, m > 0), and in Case III, the drug does both (k, m > 0). Unless otherwise noted, we assume that the proportion of sensitive cells at the beginning of treatment is the equilibrium proportion  $\bar{f}_0(0)$  in the absence of drug (Section 4.5).

## 2.1.1 Characteristics of the optimal treatment

For Case I, the optimal dosing strategy on [0, T] applies a constant dose  $c^*$ , significantly smaller than the maximum allowed dose  $c_{\max}$ , for most of the treatment period (Figure 2,

top left panel). Towards the end of the period, the dose is gradually increased to  $c_{\text{max}}$ . This final part of the treatment is a boundary effect which arises due to a myopic desire to minimize the tumor size at time T, with no regard for what is best in the long run. If we were to extend the treatment horizon beyond time T, the period applying the constant dose  $c^*$  would be extended (Figure S1). In what follows, we will ignore this boundary effect and focus on what is optimal over a long time horizon, which for Case I is constant dose application.

For Case II, the optimal strategy starts with the maximum dose  $c_{\text{max}}$  and gradually decreases it until it settles into a constant dose  $c^*$ , which is even smaller than the constant dose for Case I (Figure 2, top middle panel). In Case I, when  $\mu(c)$  increased linearly as a function of c, it was not desirable to apply large drug doses at the beginning of treatment, since this would induce too many sensitive cells to adopt drug tolerance. In Case II, when the drug only affects  $\nu(c)$ , the sensitive population can be reduced quickly at the beginning of treatment without the downside of promoting transitions from sensitivity to tolerance.

For Case III, the optimal policy has characteristics of both previous cases, as it does apply larger doses in the beginning, but it does not start with the maximum dose, to avoid overly promoting transitions from sensitivity to tolerance (Figure 2, top right panel). In all three cases, the optimal strategy involves both a transient phase and a constant-dose equilibrium phase. During the equilibrium phase, the tumor is maintained at a fixed composition between sensitive and tolerant cells, as is shown in the second row of Figure 2.

Using mathematical analysis, we can generalize these insights beyond the baseline parameter setting used in Figure 2 (Section 4.8). More precisely, we can prove that the long-run average growth rate of the tumor is minimized by a constant-dose strategy, irrespective of the model parameter values (Section S1.2). Moreover, the best long-run dose  $c^*$  is simply the dose which minimizes the equilibrium growth rate  $\sigma(c)$  under a constant dose c, as is confirmed by the dotted lines in Figure 2 (Section S1.2). This means that the simple explicit expression (1) for  $\sigma(c)$  can be used to address questions concerning ultimate treatment success. For example, if for a particular cancer type and a particular drug, we are interested in knowing whether there exists *any* dosing schedule capable of driving long-run tumor reduction, we simply need to check whether there exists a constant dose c such that  $\sigma(c) < 0$ .

#### 2.1.2 Understanding the transient phase

In the long run, the optimal treatment applies a constant dose  $c^*$  which maintains the tumor at a desired composition between sensitive and tolerant cells. In the bottom row of Figure 2, we compare the optimal strategy with the constant-dose strategy applying the equilibrium dose  $c^*$  throughout. Eventually, the tumor reduces at the same rate  $\sigma(c^*)$  under both strategies. However, during the transient phase, the optimal strategy reduces the tumor much faster under Cases II and III, and the difference in tumor size is maintained throughout the course of treatment. These examples show that there can be significant long-term benefits to adopting a different strategy during the transient phase than the equilibrium phase.

We next seek to understand what drives dose selection during the transient phase. At the beginning of treatment, the proportion of sensitive cells in the tumor is  $\bar{f}_0(0)$ , the equilibrium proportion in the absence of drug. Over the course of the transient phase, this proportion is reduced to the equilibrium proportion  $\bar{f}_0(c^*)$  corresponding to the best long-run dose  $c^*$ . We can show that once the proportion of sensitive cells reaches level  $f_0$  with  $\bar{f}_0(c^*) < f_0 < \bar{f}_0(0)$ ,



Figure 2: Optimal dosing under linear induction of tolerance. The top row shows optimal dosing strategies under linear induction of tolerance computed using the forwardbackward sweep method. Three cases are considered: In Case I, the drug only elevates transitions from sensitivity to tolerance, in Case II, the drug only inhibits transitions back, and in Case III, it has both effects simultaneously (gray panels). In all cases, the optimal dosing strategy involves both a transient phase and an equilibrium phase. During the equilibrium phase, a constant dose  $c^*$  is applied which maintains the tumor at a fixed composition between sensitive and tolerant cells (second row). The optimal long-run dose  $c^*$  is precisely the dose which minimizes the equilibrium growth rate  $\sigma(c)$  under a constant dose c, which is indicated by the dotted lines. In the bottom row, the tumor size evolution under the optimal strategy is compared with the tumor size evolution under the constant-dose strategy applying  $c^*$  throughout. The tumor eventually decays at the same exponential rate under both strategies. For Case I, there is no difference between the two strategies. For Cases II/III, the optimal strategy results in 85.6%/55.4% greater tumor reduction during the initial stages of treatment, and 59.4%/24.2% greater tumor reduction long-term. Thus, there can be significant benefits to adopting a different strategy during the transient phase than the equilibrium phase.



Figure 3: Understanding the transient phase of the optimal treatment. (a) The optimal dosing strategy eventually maintains the tumor at a fixed equilibrium composition. During the transient phase of treatment, the most naive strategy would be to apply the maximum dose  $c_{\rm max}$  to maximize cell kill and steer the tumor as quickly as possible into the equilibrium composition. However, this would build up a large population of drugtolerant cells through drug-induced transitions from sensitivity to tolerance. We can show that during the transient phase, whenever the proportion of sensitive cells is  $f_0$ , the optimal dose to give at that moment maximizes the ratio  $(\sigma(c^*) - u(c, f_0))/(-f'_0)$ , where  $u(c, f_0)$  is the instantaneous tumor growth rate. This ratio precisely quantifies how the optimal treatment must balance cell kill and tolerance induction during the initial stages of treatment. It also gives a simple method for computing the transient phase, where the ratio ( $\sigma(c^*)$  –  $u(c, f_0))/(-f'_0)$  is maximized and the value for  $f_0$  is updated iteratively. (b) The transient phase computed using the approach laid out in (a) (blue lines) agrees with the transient phase computed using the forward-backward sweep method (dotted lines). (c) If the proportion of sensitive cells  $f_0(0)$  at the start of treatment is changed, only the transient phase of the optimal treatment is affected, since the optimized equilibrium dose  $c^*$  remains the same. For Case I, the transient phase is independent of the initial condition.

the optimal dose c to give at that moment is obtained by maximizing

$$\frac{\sigma(c^*) - u(c, f_0)}{-f_0'},\tag{3}$$

where  $u(c, f_0) = (\lambda_0(c) - \lambda_1)f_0 + \lambda_1$  is the instantaneous tumor growth rate (Section S1.4). In Figure 3(a), we show how the transient phase of the optimal treatment can be computed by iteratively determining the maximizing dose c in (3) and updating value of  $f_0$ . In Figure 3(b), we confirm that the transient phase computed using this approach agrees with the results of Figure 2 obtained using the forward-backward sweep method.

The most naive dosing strategy to move the sensitive cell proportion from the starting value  $\bar{f}_0(0)$  to the final value  $\bar{f}_0(c^*)$  would be to apply the maximum dose  $c_{\max}$  continuously, thereby reducing the sensitive cell proportion as quickly as possible. This strategy would lead to the lowest possible instantaneous growth rate  $u(c, f_0)$  and thus the largest possible numerator  $\sigma(c^*) - u(c, f_0)$  in (3). However, under drug-induced tolerance, applying the maximum dose has the downside of encouraging a large number of sensitive cells to adopt drug tolerance, thereby building up a large population of tolerant cells. This is encapsulated by the presence of the denominator  $-f'_0$  in (3), which quantifies the increase in the number of drug-tolerant cells relative to drug-sensitive cells. Overall, expression (3) describes precisely how the optimal strategy must balance the trade-off between sensitive cell kill and tolerance induction as it steers the tumor into the optimal equilibrium composition.

So far, we have assumed that the starting proportion of sensitive cells is  $\bar{f}_0(0)$ . We note here that if the initial tumor composition were changed, which could for example be the case in a controlled *in vitro* setting, this would only affect the transient phase of the optimal strategy (Figure 3(c)). In addition, we note that when  $f_0(0) < \bar{f}_0(c^*)$ , the optimal strategy applies a dose lower than the equilibrium dose  $c^*$  during the transient phase.

#### 2.1.3 Comparison with pulsed treatments

For all three cases considered in Figure 2, it is optimal in the long run to expose the tumor continuously to drug at a majority drug-tolerant composition. We now investigate how the optimal treatment compares with pulsed treatments, where the tumor is taken periodically off drug to allow tolerant cells to revert back to sensitivity. This comparison is made using the long-run average growth rate of the tumor, defined in Section 4.6.

We consider a pulsed schedule as a triple  $(c, t_{cycle}, \varphi)$  which describes the drug dose c, the duration of each treatment cycle  $t_{cycle}$ , and the proportion of time  $\varphi$  the drug is applied during each cycle. A constant schedule is considered a pulsed schedule with  $\varphi = 1$ . It is relatively simple to show that in our model, for any pulsed schedule  $(c, t_{cycle}, \varphi_1)$ , there exists a schedule  $(c, t_{cycle}/2, \varphi_2)$  with half the cycle length which yields the same or lower long-run growth rate (Section S1.5). Therefore, when investigating pulsed schedules, it is sufficient to consider idealized schedules with an arbitrarily short cycle length. However, it is also simple to show that once the cycle length has become sufficiently small, the long-run average growth rate becomes effectively invariant to the cycle length (Section S1.5). Thus, even if the best pulsed schedule involves switching arbitrarily fast between drug and no drug, a comparable outcome can be obtained using a much longer cycle time. This is an important insight, as it both means that the model-recommended pulsed schedule is more clinically feasible, and it enables the extension of treatment breaks up to a certain point without adversely affecting the outcome.



Figure 4: **Pulsed schedules under linear induction of tolerance.** The top panels show the long-run average growth rate of the tumor under a range of possible pulsed schedules of the form  $(c, \varphi)$ , where c is the drug dose applied and  $\varphi$  is the proportion of drug exposure. The length of each treatment cycle is assumed arbitrarily short. The red curves show for each exposure proportion  $\varphi$  the optimal dose  $c^*(\varphi)$  to give. The red dots show the optimal pulsed schedules, which are continuous schedules for Cases I, II and III, consistent with our results in Figure 2. The middle panels show for each  $\varphi$  the long-run average tumor growth rate a under the optimal dose  $c^*(\varphi)$  and the bottom panels show the average dose applied during each cycle, normalized to the average dose under the optimal schedule. The middle and bottom panels show that the optimal schedule is quite sensitive to the duration of drug exposure, with treatment efficacy deteriorating quickly and a significantly larger average dose being required once breaks of 20–30% or longer are taken. If treatment breaks are desired for toxicity or other reasons, the plots in this figure could help a clinician understand the downsides of instituting breaks of a certain length and the optimal dose to give for that length.

For a given pulsed schedule  $(c, \varphi)$  with an arbitrarily short cycle length, the long-run average growth rate of the tumor can be computed using the relatively simple formula (21). In the top panels of Figure 4, we have computed the long-run growth rate for a wide range of possible pulsed schedules  $(c, \varphi)$  under Cases I, II and III. The red lines show for each proportion  $\varphi$  of drug exposure the optimal dose  $c^*(\varphi)$  to administer, and the red dots indicate the optimal schedules. As expected, a constant low dose is optimal in the long run. In addition, the bottom two panels of Figure 4 show that for all three cases, the optimal schedule is quite sensitive to the duration of drug exposure. Instituting treatment breaks of 20–30% or longer results in a significantly larger tumor growth rate and a significantly larger average dose being required to achieve that growth rate. From a clinical perspective, understanding to what extent the optimal strategy can be perturbed to insert treatment breaks can be useful for reducing potential side effects of continuous drug exposure. Plots like those in Figure 4 could help a clinician understand the implications of instituting treatment breaks of a certain length, and to determine which dose is best for that length.

## 2.2 Optimal dosing under uniform induction of tolerance

We now consider the case where drug tolerance is induced in a uniform fashion, meaning that the drug effect is constant whenever the drug is present (Section 4.3). The transition rate functions  $\mu(c)$  and  $\nu(c)$  are discontinuous in this case, implying that there may not exist an optimal solution, and we found that the forward-backward sweep method does not converge to a unique solution. Fortunately, the mathematical tools we have built for analyzing linearly induced tolerance can be used to characterize the uniformly induced case.

We begin by considering pulsed schedules  $(c, \varphi)$  with an arbitrarily short cycle length, where the long-run average tumor growth rate can be computed using (21) as before. Figure 5(a) reveals a striking difference between the cases of uniform and linear induction of tolerance. First, for each given proportion of drug exposure  $\varphi$ , it is optimal to apply the maximum dose  $c_{\text{max}}$ , as indicated by the red lines. Second, for Case I, it is optimal to apply the maximum dose continuously, and for Cases II and III, it is optimal to alternate between the maximum dose and no dose, as indicated by the red dots. Thus, whereas low-dose continuous treatments are optimal in the long run under linear induction of tolerance, for uniform induction, it is optimal to apply the maximum dose either continuously or in a pulsed fashion. We can prove this mathematically using arguments similar to the linear case (Section S1.2). This result is intuitive since under uniform induction, once any drug dose is applied, there is no downside in applying a larger dose as it does not further induce transitions to tolerance.

In Figure 5(b), we show the optimal proportion of drug exposure  $\varphi^*$  for a range of possible values of the drug effects  $\Delta \mu = \mu_{\text{max}} - \mu_0$  and  $\Delta \nu = \nu_0 - \nu_{\text{min}}$ , assuming that the maximum dose  $c_{\text{max}}$  is used. When  $\Delta \nu$  is small, it is always optimal to apply the maximum dose continuously, independently of the value of  $\Delta \mu$ . In other words, when the drug primarily influences transitions from sensitivity to tolerance, continuous maximal dosing is optimal in the long run, independently of the level of drug induction. On the other hand, when the drug primarily influences transitions from tolerance to sensitivity, the optimal proportion  $\varphi^*$ changes significantly with the value of  $\Delta \nu$ . Furthermore, for the largest values of  $\Delta \nu$ , it is optimal to institute treatment breaks of 30% or longer, irrespective of the value of  $\Delta \mu$ . This reflects the different roles  $\mu$  and  $\nu$  play in the evolutionary dynamics of the tumor. Under a large drug dose, tumor growth is primarily driven by drug-tolerant cells, which grow at net rate  $\lambda_1 - \nu(c)$ . Thus, whereas increasing  $\mu$  will primarily decrease the proportion of sensitive



Figure 5: Pulsed schedules under uniform induction of tolerance. (a) Under uniform induction of tolerance, the transition rate from sensitivity to tolerance is increased by  $\Delta \mu =$  $\mu_{\rm max} - \mu_0$  in the presence of drug, and the transition rate from tolerance to sensitivity is decreased by  $\Delta \nu = \nu_0 - \nu_{\min}$ . The heatmaps show the long-run average tumor growth rate for a range of possible pulsed schedules of the form  $(c, \varphi)$  under Cases I, II and III. The red curves show each for exposure proportion  $\varphi$  the optimal dose  $c^*(\varphi)$  to give, and the red dots show the optimal pulsed schedules. For each possible exposure proportion  $\varphi$ , it is optimal to apply the maximum dose  $c_{\text{max}}$ . For Case I, where the drug only affects transitions from sensitivity to tolerance, it is optimal to apply the maximum dose continuously. For Cases II and III, it is optimal to alternate between the maximum dose and no dose. (b) The heatmap in the left panel shows the optimal proportion of drug exposure  $\varphi^*$  as a function of  $\Delta \mu$  and  $\Delta \nu$ , given that the maximum dose  $c_{\text{max}}$  is applied. The drug effects  $\Delta \mu$  and  $\Delta \nu$  are measured relative to the transition rates  $\mu_0$  and  $\nu_0$  in the absence of drug. The middle panel shows that for  $\Delta \mu/\mu_0 = 10^{-2}$ , when the drug effect on  $\mu$  is small relative to  $\mu_0$ , the optimal proportion  $\varphi^*$  changes significantly with  $\Delta \nu$ . However, the right panel shows that when  $\Delta \nu / \nu_0 = 10^{-2}$ , the optimal proportion is invariant to  $\Delta \mu$ . In fact, it is optimal to apply the maximum dose continuously, irrespective of the value of  $\Delta \mu/\mu_0$ . This reflects the different roles  $\mu$  and  $\nu$  play in the evolutionary dynamics of the tumor.



Figure 6: **Optimal dosing under uniform induction of tolerance.** Under uniform induction of tolerance, we can prove that during the transient phase, it is optimal to apply the maximum dose throughout, and during the equilibrium phase, it is optimal to apply a pulsed schedule  $(c_{\max}, \varphi)$  alternating between the maximum allowed dose  $c_{\max}$  and no dose (possibly with  $\varphi = 1$ ). Examples of optimal strategies are shown for Cases I, II and III. For Case I, where the drug only increases transitions from sensitivity to tolerance, it is optimal to apply the maximum dose continuously throughout the entire treatment period. These examples show that drug-induced tolerance does not necessarily lead to optimality of low doses, rather, it is important to understand the exact nature of drug-induced tolerance.

cells in the tumor, decreasing  $\nu$  will directly increase the long-run tumor growth rate.

For the transient phase of the optimal treatment, we can use the approach outlined for the linear case in Section 2.1.2. Indeed, under uniform induction, the long-run optimal pulsed schedule  $(c_{\max}, \varphi^*)$  maintains the tumor at the equilibrium proportion  $\bar{f}_0(c_{\max}, \varphi^*)$  given by (22), and the goal is to steer the tumor optimally into this composition. With similar reasoning to the linear case, we can show that once the proportion of sensitive cells reaches the level  $f_0$  with  $\bar{f}_0(c_{\max}, \varphi^*) < f_0 < \bar{f}_0(0)$ , the optimal dose c to give is obtained by maximizing

$$\frac{\sigma(c_{\max},\varphi^*) - u(c,f_0)}{-f'_0} \tag{4}$$

under the constraint  $f'_0 < 0$ . In fact, we can go further and show that (4) is maximized when  $c = c_{\text{max}}$  (Section S1.4). In other words, the optimal transient strategy is to apply the maximum dose  $c_{\text{max}}$  continuously until the equilibrium proportion  $\bar{f}_0(c_{\text{max}}, \varphi^*)$  is reached.

We can now combine the analysis of the previous paragraphs to compute optimal strategies under uniform induction for Cases I, II and III (Figure 6). These strategies are qualitatively different from the strategies obtained for linear induction both during the transient and equilibrium phases (Figure 2). During the transient phase, it is optimal to apply the maximum dose continuously under uniform induction, whereas either a gradually decreasing or a constant low-dose schedule is preferred under linear induction. During the equilibrium phase, Case I involves continuous maximal dosing for uniform induction and constant low dosing for linear induction, whereas Cases II and III involve alternation between the maximum dose and no dose for uniform induction compared to a constant low dose for linear induction. These results show that drug-induced tolerance does not necessarily lead to optimality of low doses, and they underscore the importance of understanding the exact nature of drug induction before the optimal dosing strategy can be determined. However, same as for the linear case, the optimal treatment involves a transient and an equilibrium phase, where the goal of the transient phase is to steer the tumor to a desired composition, and the goal of the equilibrium phase is to maintain the tumor at that composition.

In the preceding discussion, we have referred to a strategy alternating between the maximum dose and no dose arbitrarily fast as the optimal long-run strategy. Since this is an idealized treatment schedule, it is more precise to say that there exists a sequence of pulsed strategies which achieve the optimal long-run growth rate in the limit as  $t_{cycle}$  approaches zero. However, just as for the case of linear induction, the cycle length can be extended significantly without affecting the long-run average growth rate of the tumor.

## 2.3 Application: In vitro persistence in colorectal cancer

So far, we have sought to gain general insights into optimal dosing strategies under several possible forms of drug-induced tolerance, using both computational and mathematical tools. We now show how our approach can be combined with *in vitro* data to derive the optimal strategy for a particular type of cancer. In Russo et al. [18], the authors treated two colorectal cancer cell lines with increasing doses of anti-cancer agents, and they used their data to parametrize mathematical models of drug-induced persistence (Section S1.6). They found that when BRAF V600-E mutated WiDr colorectal cancer cells were treated with a combination of dabrafenib and cetuximab, the drugs elevated transitions from a drug-sensitive to a drug-persistent state linearly with the drug dose (Case I under linear induction of tolerance). For RAS/RAF wild-type DiFi cells treated with cetuximab, the same transitions were elevated uniformly as a function of the dose (Case I under uniform induction of tolerance).

According to our analysis in the previous section, we already know that for the DiFi cells, it is optimal to apply the maximum dose continuously. We therefore focus on the WiDr cells and compare the optimal strategy with dosing regimens considered in [18]. For the purposes of this analysis, we adopt the model of drug effect on cell proliferation from [18] (Section S1.6). As expected from our analysis in Section 2.1.1, the optimal strategy over a treatment horizon of T = 100 days applies a constant dose continuously, once again ignoring the boundary effect at the very end (Figure 7(a)). The optimal dose is even smaller here than for the examples considered in Section 2.1.1 or  $c^* = 0.85$  as a proportion of the  $EC_{50}^d$ dose (in absolute terms, the  $EC_{50}^d$  dose is  $2.3779 \cdot 10^{-7} M$  and the optimal dose is  $2 \cdot 10^{-7}$ M). One reason that the optimal dose is lower than the  $EC_{50}^d$  dose in this case is that the dose at which the net sensitive cell division rate  $\lambda_0(c)$  becomes negative is much smaller than the  $EC_{50}^d$  dose, meaning that the tumor reduces in size even at  $c^* = 0.85$  (Section S1.6).

In [18], the authors considered a shorter time horizon of T = 10 days, and they compared a constant dose schedule with c = 4.2, relative to the  $EC_{50}^d$  dose, with a linearly increasing dose schedule involving the same average dose  $\bar{c} = 4.2$  over the horizon (Figure 7(b)). They observed that the linearly increasing schedule significantly outperformed the constant-dose schedule, which is confirmed by our analysis (Figure 7(d)). However, we note that the considerable preference for the linear schedule is due to the constant-dose schedule with c = 4.2 being significantly suboptimal. For example, the long-run optimal dose  $c^* = 0.85$  leads to a similar tumor decay over T = 10 days as the linear schedule with  $\bar{c} = 4.2$  (Figure 7(c)). The optimal short-term strategy over T = 10 days applies small doses for most of the period, starting at c = 0.91, before increasing the dose at the very end (Figure 7(b)). The optimal short-term strategy achieves a 17% greater tumor reduction than the linear strategy, while applying less than half as much cumulative dose, or  $\bar{c} = 2.0$  on average.

Here, we have evaluated the treatment schedules in terms of the tumor size at the end of the treatment horizon. In [18], the authors considered a different metric of treatment success, the number of persister cells induced under treatment, assuming no persister cells at the beginning of treatment. Even under this metric, the optimal short-term strategy outperforms the linearly increasing schedule, and in fact, the optimal long-run dose  $c^* = 0.85$ performs the best (Figure 7(d)). From one perspective, this is not surprising, since if the goal is to minimize the number of sensitive cells that the drug induces to adopt persistence, it is optimal to give no drug and thus induce no sensitive cells to adopt persistence. On the other hand, the fact that the optimal long-run dose induces fewer persister cells than the other three schedules in the short term is precisely why it is better in the long run.

In summary, the constant-dose strategy with c = 0.85 is both successful at restricting persister evolution in the short term and optimally controlling the tumor in the long term. In addition, it applies around an 80% lower cumulative dose than the linear schedule with average dose  $\bar{c} = 4.2$ . These results demonstrate the utility of our approach for identifying optimal low-dose strategies in an *in vitro* setting. Determining the optimal dose, understanding how it affects the tumor in the short and long term, and comparing it with other potential dosing strategies would be difficult without the mathematical model.

## 3 Discussion

In this work, we have investigated optimal dosing of anti-cancer treatment under drug-induced tolerance. We found that the optimal strategy always involves both a transient phase and an equilibrium phase. During the equilibrium phase, the tumor is maintained at a fixed intratumor composition which minimizes its long-run growth rate. Under linear induction of tolerance, the optimal equilibrium strategy is to apply a low constant dose, while under uniform induction of tolerance, it is optimal to alternate between the maximum allowable dose and no dose. We proved this mathematically and provided simple methods for computing the optimal equilibrium strategies. During the transient phase, the optimal strategy steers the tumor into the desired long-run composition while precisely balancing the trade-off between maximal cell kill and tolerance induction. We found that the directionality of drug induction. whether the drug elevates transitions from sensitivity to tolerance or inhibits transitions back, significantly affects the optimal strategy, due to the different roles these transitions play in the evolutionary dynamics. Finally, we applied our methology to a recently published in vitro dataset involving drug-induced tolerance [18], and we used it to identify an optimal low-dose treatment strategy which outperforms strategies suggested in the original work, whether in terms of short-term persistence induction, long-term tumor control or cumulative dose.

We view this work as an initial step towards a more complete understanding of optimal dosing under drug-induced plasticity. We have left many important questions unaddressed which serve as a guide for future work. First, we have only considered the extreme cases



Figure 7: Optimal dosing for an *in vitro* colorectal cancer system. (a) For BRAF V600-E mutated WiDr cells, Russo et al. [18] observed linearly increasing transitions from sensitivity to tolerance under dabrafenib + cetuximab treatment. Under a sufficiently long time horizon, the optimal dosing strategy applies a low constant dose equal to 85% of the  $EC_{50}^d$  dose. (b) In [18], the authors consider both a constant strategy and a linearly increasing strategy with average dose  $\bar{c} = 4.2$  (relative to the EC<sup>d</sup><sub>50</sub> dose) using a time horizon of T = 10days. The optimal strategy over T = 10 days applies small doses during most of the period and increases the dose towards the end of the horizon. (c) The linearly increasing schedule with average dose  $\bar{c} = 4.2$  outperforms the constant-dose schedule with the same average dose in terms of tumor reduction over T = 10 days, which is consistent with the results of [18]. However, the optimal strategy over T = 10 days achieves a 17% greater tumor reduction while applying half as much dose. Moreover, the optimal long-run constant dose  $c^* = 0.85$ achieves similar tumor reduction to the linear strategy at less than 20% of the cumulative dose. (d) Out of the four schedules considered in part (b), the optimal long-run constant dose  $c^* = 0.85$  induces the fewest sensitive cells to adopt persistence over T = 10 days. Overall, this constant-dose schedule is successful both in restricting persister evolution in the short term and maximally reducing the tumor in the long term.

where tolerance is induced in a linear or uniform fashion. If the transition rate functions  $\mu(c)$ and  $\nu(c)$  follow more general Michaelis-Menten or Hill dynamics [40, 41], it may be difficult to apply optimal control analysis, but the optimal pulsed strategy can always be determined using the explicit expression (21). Second, while we have focused here on the dynamics between sensitive and tolerant cells, there is evidence that prolonged drug exposure can induce epigenetic reprogramming of tolerant cells and eventually lead to stable drug resistance [7, 11]. Tolerant cells can also form a reservoir for the evolution of genetic resistance [9, 10, 18]. Optimally delaying resistance in this case may require different dosing strategies which avoid prolonged drug exposure. Nevertheless, we believe that our analysis of the dynamics between sensitive and tolerant cells will be an important ingredient to understanding the more complex dynamics. Third, we have considered an exponential growth model without competitive or cooperative dynamics. If tumor growth is constrained by a carrying capacity, our insights will continue to hold whenever it is possible to kill the tumor, since then the carrying capacity will not significantly affect the dynamics. However, if recurrence cannot be avoided, it may become optimal to keep the tumor close to the carrying capacity to avoid releasing tolerant cells from competition with sensitive cells [42, 28, 30]. This will be important to explore in future work. Finally, we have equated drug dose with drug concentration throughout and ignored the effect of pharmacokinetics. Confirming the clinical applicability of our approach would require an investigation of these dynamics, particularly for the case of uniform tolerance induction, where the dynamics are significantly different depending on whether the drug is present or not.

Applying our insights to a specific cancer type requires understanding the quantitative dynamics of drug induction for that cancer type. Russo et al. [18] have suggested a Bayesian approach for inferring the transition rate function  $\mu(c)$  from sensitivity to tolerance using *in vitro* tumor bulk data, but their work only distinguishes between the extreme cases of linear and uniform induction of tolerance. In a recent work, we have suggested a maximum likelihood framework for inferring more general dose-response dynamics for  $\mu(c)$  based on the Hill equation [43]. However, as we have discussed, it is also plausible that the drug inhibits the transition rate  $\nu(c)$  from tolerance back to sensitivity, or that the drug simultaneously affects both rates. In general, the present work shows that the optimal strategy varies significantly depending on the exact dynamics of drug induction. This suggests the need for the development of integrated experimental data, which may require data on the phenotypic composition of the tumor [44]. Ultimately, these integrated tools could help usher in a new era of precision medicine, where the dynamics of drug induction are determined and dosing strategies are optimized on an individual patient basis [45, 46, 25, 47].

#### Connection with previous work

We conclude by discussing the connection of our work to previous work, which is reviewed in more detail in [48]. Kuosmanen et al. [31] studied optimal dosing under linearly induced irreversible transitions  $\mu(c)$  from sensitivity to resistance, and they sought to minimize the probability of resistance forming under treatment given an initially drug-sensitive tumor. They showed it was best to administer constant low doses even under a modest level of druginduced resistance, which is consistent with our results. Greene et al. [28, 30] considered a Lotka-Volterra competition model between sensitive and resistant cells, where they assumed that both  $d_0(c)$  and  $\mu(c)$  were linear in c, with transitions from sensitivity to resistance once again being irreversible. In [28], they showed that intermittent treatment can be preferable to constant treatment under drug-induced resistance, although this comparison was based on a single possible dose value. In [30], the authors studied the same model using optimal control theory, where the goal was to maximally delay tumor recurrence. The optimal dosing strategies varied significantly with the specific model parameter values, involving periods of maximum dosing, no dosing, and small constant dosing. We note that Greene et al.'s assumption of competition between sensitive and resistant cells fundamentally changes the model dynamics. Under this assumption, it becomes counterproductive to apply large drug doses even when the drug does not induce resistance, since aggressive strategies release resistant cells from competition with sensitive cells. Investigating how these dynamics may influence our optimal dosing strategies is an important direction for future inquiry.

In Angelini et al. [32], the authors studied a model of phenotypic switching where both  $d_0(c)$  and  $\mu(c)$  were of the form  $c \mapsto k(1+e^{-r(c-s)})^{-1}$ , which has a sigmoidal shape. They only considered constant-dose schedules. Their results indicate that when  $\mathrm{EC}_{50}^d \approx \mathrm{EC}_{50}^\mu$ , meaning that the  $\mathrm{EC}_{50}$  dose is similar for  $d_0(c)$  and  $\mu(c)$ , applying the maximum dose  $c_{\max}$  is optimal. However, when  $\mathrm{EC}_{50}^\mu \gg \mathrm{EC}_{50}^d$ , lower doses become optimal. This is consistent with our results, since under the case  $\mathrm{EC}_{50}^\mu \gg \mathrm{EC}_{50}^d$ ,  $\mu(c)$  can be approximated by a linear function in c, as discussed in Section 4.3. We have also shown that when  $\mathrm{EC}_{50}^\mu \ll \mathrm{EC}_{50}^d$ , in which case  $\mu(c)$  can be considered approximately constant in c for c > 0, it is optimal to apply the maximum dose continuously. In combination, our work and [32] indicate that drug-induced tolerance does not lead to optimality of small doses in and of itself. Our work furthermore shows that if the drug inhibits the transition rate  $\nu(c)$  from tolerance to sensitivity, applying the maximum dose continuously is generally suboptimal, irrespective of the relationship between  $\mathrm{EC}_{50}^d$  and  $\mathrm{EC}_{50}^\nu$ . In general, our work illustrates the importance of understanding the exact nature of drug-induced resistance before treatment recommendations can be made.

One of the most similar works to ours is Akhmetzhanov et al. [29], where the authors study a model of resistance in BRAF-mutant melanoma, involving two mutually inhibitory biological pathways. Their baseline model has three cell types, corresponding to an active main pathway (type-1), active alternative pathway (type-2), or both pathways inactive (type-0), with reversible transitions  $1 \leftrightarrow 0 \leftrightarrow 2$ . With some simplifying assumptions, the authors reduce their model to a two-type model involving sensitive and resistant cells, where the rates  $d_0(c), \mu(c)$  and  $\nu(c)$  are dose-dependent. However, the transitions between states emerge from an underlying model of a particle undergoing Brownian motion inside a double-well potential, which results in  $d_0(c)$ ,  $\mu(c)$  and  $\nu(c)$  having more complex forms than we have assumed. Nevertheless, Akhmetzhanov et al. [29] arrive at an optimal strategy similar to the one we derived for linearly induced tolerance (Cases II and III), where large initial doses are followed by a small constant dose. The authors note that the constant dose appears to maintain the population at an optimal composition and that the goal of the optimal treatment appears to be to reach this composition as quickly as possible. Our work shows that the composition is optimal in the sense that it minimizes the equilibrium tumor growth rate  $\sigma(c)$ , and it offers a simple way of computing the equilibrium dose through minimization of  $\sigma(c)$ . It also shows that the optimal strategy does not necessarily steer the tumor into the desired longrun composition as quickly as possible. This is especially true when the drug only influences transitions from sensitivity to resistance, in which case it is optimal to apply a small dose throughout. Rather, the optimal strategy must balance the trade-off between cell kill and tolerance induction in a way we have precisely quantified.

It is finally worth mentioning a recent work by Cassidy et al. [49], where it is assumed

that the probability of switching between a sensitive and tolerant state depends on the cell's age. The authors do not assume that the drug influences the switching dynamics, but rather that drug-tolerant cells cooperate to divide faster with increasing frequency in the population. Similar to the model of Greene et al., it is counterproductive to maximally kill the drug-sensitive cells in this case, as it triggers cooperation between the tolerant cells. In the context of non-small cell lung cancer [50], Cassidy et al. show that an adaptive therapy aimed at limiting the frequency of tolerant cells in the population outperforms a pulsed schedule applying a fixed dose every 7 days. While the authors do not investigate optimal dosing strategies, it is interesting to note that their adaptive therapy ultimately maintains the tumor around a certain composition between sensitive and tolerant cells. The principle of an optimal composition between sensitive and tolerant cells may therefore continue to apply even if our model is extended to account for potential group behavior.

## 4 Methods

## 4.1 Model of cell proliferation and phenotypic switching

Our baseline model is a multi-type branching process model in continuous time [51]. In the model, cells switch stochastically between two distinct cell states, a drug-sensitive state (type-0) and a drug-tolerant state (type-1). In the absence of drug, a type-0 cell divides into two type-0 cells at rate  $b_0$ , it dies at rate  $d_0$  and it transitions to the tolerant type-1 state at rate  $\mu > 0$ . More precisely, each type-0 cell waits an exponentially distributed amount of time with rate  $a_0 := b_0 + d_0 + \mu$  before it either divides with probability  $b_0/a_0$ , dies with probability  $d_0/a_0$ , or transitions to type-1 with probability  $\mu/a_0$ . A type-1 cell divides at rate  $b_1$ , it dies at rate  $d_1$ , and it reverts to type-0 at rate  $\nu > 0$  (Figure 1(a)). The net birth rates of the two types are denoted by  $\lambda_0 := b_1 - d_1$  and  $\lambda_1 := b_1 - d_1$ .

## 4.2 Drug effect on cell proliferation

To model the effect of the anti-cancer drug on cell proliferation, we assume that the sensitive cell death rate  $d_0$  is an increasing function of the current drug dose c. For simplicity, we assume that the drug-tolerant cells are unaffected by the drug. The specific functional form for  $d_0$  is the Michaelis-Menten function, which is commonly used for this purpose:

$$d_0(c) = d_0 + (d_{\max} - d_0) \cdot \frac{c}{c + \mathrm{EC}_{50}^d} = d_0 + \Delta d_0 \cdot \frac{c}{c + \mathrm{EC}_{50}^d}.$$
 (5)

Here,  $d_0$  is the sensitive cell death rate in the absence of drug,  $d_{\max}$  is the saturation death rate under an arbitrarily large drug dose,  $\Delta d_0 := d_{\max} - d_0 \ge 0$  is their difference, and  $\mathrm{EC}_{50}^d$ is the dose at which the drug has half the maximal effect on sensitive cell proliferation. Note that we write simply  $d_0$  instead of  $d_0(0)$  to signify the death rate in the absence of drug. The function in (5) is concave, but it is worth noting that if the the drug dose is viewed on a log scale, then (5) becomes an S-shaped dose response curve which is characteristic of viability curves in the biological literature (Figure 8).

Expression (5) can be rewritten as

$$d_0(c) = d_0 + \Delta d_0 \cdot \frac{(c/\text{EC}_{50}^d)}{(c/\text{EC}_{50}^d) + 1}.$$



Figure 8: **Drug effect on sensitive cell death rate**  $d_0$ . The Michaelis-Menten function (5) describing the drug effect on cell proliferation is concave in the drug dose c (left panel). When the dose c is viewed on a log scale, the function becomes takes on an S-shape which is characteristic of viability curves in the biological literature (right panel).

Thus, if we measure the drug dose as a proportion of the  $EC_{50}^d$  dose, we obtain the simpler expression

$$d_0(c) = d_0 + \Delta d_0 \cdot \frac{c}{c+1}.\tag{6}$$

We will usually adopt this scaling of the drug dose and use the simpler form for  $d_0(c)$ . Similarly, the net birth rate of sensitive cells is given by

$$\lambda_0(c) = b_0 - d_0(c) = \lambda_0 - \Delta d_0 \cdot \frac{c}{c+1}.$$
(7)

Note that we again write simply  $\lambda_0$  instead of  $\lambda_0(0)$ .

In the preceding formulation, we have assumed that the drug is cytotoxic, meaning that it induces cell death. We could have equivalently assumed that the drug is cytostatic, meaning that it reduces the sensitive cell division rate  $b_0$ . The net birth rate  $\lambda_0(c)$  is what is important for our investigation, which has the form given in (7) in both cases.

## 4.3 Drug effect on switching rates

To model the possibility of drug-induced tolerance, we assume that in the presence of the anti-cancer drug, one or both of the transition rates  $\mu$  and  $\nu$  change with the drug dose c. If we focus first on the transition rate  $\mu$  from sensitivity to tolerance, it is natural to assume that it follows a Michaelis-Menten function of the form (5):

$$\mu(c) = \mu_0 + (\mu_{\max} - \mu_0) \cdot \frac{c}{c + \mathrm{EC}_{50}^{\mu}} = \mu_0 + \Delta \mu \cdot \frac{c}{c + \mathrm{EC}_{50}^{\mu}},\tag{8}$$

where  $\Delta \mu := \mu_{\max} - \mu_0 \geq 0$ . The dose at which the drug has half the maximal effect on  $\mu$ ,  $EC_{50}^{\mu}$ , is in general distinct from  $EC_{50}^{d}$ . Here, we will focus on the two extreme cases where  $EC_{50}^{\mu} \gg EC_{50}^{d}$  and  $EC_{50}^{\mu} \ll EC_{50}^{d}$ . The case  $EC_{50}^{\mu} \gg EC_{50}^{d}$  means that the drug induces tolerance at doses which are already very effective at killing the sensitive cells. In this case, if the drug dose c is similar in magnitude to  $EC_{50}^{d}$ , then  $c \ll EC_{50}^{\mu}$  and by Taylor expansion:

$$\mu(c) = \mu_0 + \Delta \mu \cdot \frac{c/\text{EC}_{50}^{\mu}}{c/\text{EC}_{50}^{\mu} + 1} \approx \mu_0 + \frac{\Delta \mu}{\text{EC}_{50}^{\mu}} \cdot c.$$

In other words,  $\mu(c)$  can be treated as linearly increasing in c. The case  $\mathrm{EC}_{50}^{\mu} \ll \mathrm{EC}_{50}^{d}$  means that the drug has fully induced tolerance at low doses which are not yet effective at killing the sensitive cells. In this case, if the drug dose c is similar in magnitude to  $\mathrm{EC}_{50}^{d}$ , then  $c \gg \mathrm{EC}_{50}^{\mu}$  and by Taylor expansion for c > 0:

$$\mu(c) = \mu_0 + \Delta \mu \cdot \frac{1}{1 + \text{EC}_{50}^{\mu}/c} \approx \mu_0 + \Delta \mu = \mu_{\text{max}}.$$

In other words,  $\mu$  is effectively constant in the presence of drug.

Based on the preceding, we assume the following two functional forms for  $\mu$  (Figure 1(c)):

- (1)  $\mu(c) = \mu_0 + kc$ , where  $k \ge 0$  (tolerance is linearly induced).
- (2)  $\mu(0) = \mu_0$  and  $\mu(c) = \mu_{\text{max}}$  for c > 0 (tolerance is uniformly induced).

The reason we focus on these two extremes is twofold. First, these two exact forms were observed empirically in the recent investigation by Russo et al. [18], which is the only work we know of which has attempted to quantify drug-induced tolerance in a dose-dependent manner using *in vitro* data. Second, due to their simplicity relative to the general case (8), we are able to establish rigorous mathematical results on optimal dosing strategies.

For the transition rate  $\nu$  from tolerance back to sensitivity, the corresponding Michaelis-Menten function has the following form:

$$\nu(c) = \nu_0 + (\nu_{\min} - \nu_0) \cdot \frac{c}{c + \mathrm{EC}_{50}^{\nu}} = \nu_0 - \Delta \nu \cdot \frac{c}{c + \mathrm{EC}_{50}^{\nu}},$$

where  $\Delta \nu := \nu_0 - \nu_{\min} \ge 0$ . We will also assume the following two functional forms for  $\nu$  (Figure 1(d)):

(1)  $\nu(c) = \nu_0 - mc$ , where  $m \ge 0$ .

(2) 
$$\nu(0) = \nu_0$$
 and  $\nu(c) = \nu_{\min}$  for  $c > 0$ .

By assumption,  $\nu$  is a decreasing function of c, since we are modeling the case where the drug inhibits transitions from drug-tolerance to drug-sensitivity.

Throughout, we assume that  $\mu_0 > 0$  and  $\nu_0 > 0$ , meaning that cells are able to transition between the two states even in the absence of drug.

#### 4.4 System equations

Let  $Z_0(t)$  and  $Z_1(t)$  denote the number of sensitive and tolerant cells, respectively, at time t. Let  $n_0(t) := \mathbb{E}[Z_0(t)]$  and  $n_1(t) := \mathbb{E}[Z_1(t)]$  be the mean number of sensitive and tolerant cells at time t. These mean functions satisfy the differential equations

$$\frac{dn_0}{dt} = (\lambda_0(c) - \mu(c))n_0 + \nu(c)n_1, 
\frac{dn_1}{dt} = (\lambda_1 - \nu(c))n_1 + \mu(c)n_0.$$
(9)

Here, the dose c should be viewed as a function of time, c(t). The total population size  $n(t) := n_0(t) + n_1(t)$  obeys the differential equation

$$\frac{dn}{dt} = \lambda_0(c)n_0 + \lambda_1 n_1.$$
(10)

Let  $f_0(t) := n_0(t)/n(t)$  and  $f_1(t) := 1 - f_0(t)$  be the proportions of each cell type in the population at time t. Then

$$\frac{df_0}{dt} = \frac{(dn_0/dt) \cdot n - n_0 \cdot (dn/dt)}{n^2} 
= \frac{((\lambda_0(c) - \mu(c))n_0 + \nu(c)n_1)n - n_0(\lambda_0(c)n_0 + \lambda_1n_1))}{n^2} 
= (\lambda_0(c) - \mu(c))f_0 + \nu(c)(1 - f_0) - f_0(\lambda_0(c)f_0 + \lambda_1(1 - f_0))) 
= (\lambda_1 - \lambda_0(c))f_0^2 - (\lambda_1 - \lambda_0(c) + \mu(c) + \nu(c))f_0 + \nu(c).$$
(11)

Expression (10) can be rewritten as follows:

$$\frac{dn}{dt} = \left(\lambda_0(c)f_0 + \lambda_1(1 - f_0)\right)n 
= \left(\left(\lambda_0(c) - \lambda_1\right)f_0 + \lambda_1\right)n.$$
(12)

Solving this differential equation, the mean tumor size at time T is given by the explicit expression

$$n(T) = n(0) \exp\left(\int_0^T \left( (\lambda_0(c) - \lambda_1) f_0 + \lambda_1 \right) dt \right).$$
(13)

Expressions (12) and (13) indicate that the instantaneous growth rate of the population at time t is given by

$$u(c, f_0) := (\lambda_0(c) - \lambda_1) f_0 + \lambda_1,$$
(14)

which will be an important quantity in our investigation of optimal treatment strategies.

#### 4.5 Behavior under a constant dose

When a constant drug dose is applied, c(t) = c, all model parameters  $\lambda_0(c)$ ,  $\lambda_1$ ,  $\mu(c)$  and  $\nu(c)$  are constant. In this case, the system equations (9) admit explicit solutions. To simplify the notation, we let  $\lambda_0$ ,  $\lambda_1$ ,  $\mu$  and  $\nu$  denote the constant parameters. We first note that the dynamics of the system can be encoded in the so-called *infinitesimal generator* 

$$\mathbf{A} := egin{bmatrix} \lambda_0 - \mu & \mu \ 
u & \lambda_1 - 
u, \end{bmatrix},$$

where the (i + 1, j + 1)-th element describes the net rate at which a cell of type-*i* produces a cell of type-*j*. The infinitesimal generator has distinct real eigenvalues  $\rho < \sigma$  given by

$$\sigma = \frac{1}{2} \left( (\lambda_0 - \mu) + (\lambda_1 - \nu) + \sqrt{((\lambda_0 - \mu) - (\lambda_1 - \nu))^2 + 4\mu\nu} \right),$$
  

$$\rho = \frac{1}{2} \left( (\lambda_0 - \mu) + (\lambda_1 - \nu) - \sqrt{((\lambda_0 - \mu) - (\lambda_1 - \nu))^2 + 4\mu\nu} \right).$$

Now define

$$\delta := \frac{(\lambda_0 - \mu) - \rho}{\nu},$$
  
$$\beta := \frac{\sigma - (\lambda_0 - \mu)}{\nu}.$$

If  $n_0(0) = n$  and  $n_1(0) = m$ , the mean number of cells of each type can be written explicitly as

$$n_{0}(t) = \frac{n\delta + m}{\delta + \beta}e^{\sigma t} + \frac{n\beta - m}{\delta + \beta}e^{\rho t},$$
  

$$n_{1}(t) = \frac{\beta(n\delta + m)}{\delta + \beta}e^{\sigma t} - \frac{\delta(n\beta - m)}{\delta + \beta}e^{\rho t}.$$
(15)

These expressions indicate two important aspects of the long-run dynamics. First, the tumor eventually grows (or decays) at exponential rate  $\sigma$ . Second, the intratumor composition eventually reaches an equilibrium where the proportion between type-1 and type-0 becomes the constant  $\beta$ . We denote the equilibrium proportion of the type-0 cells as

$$\bar{f}_0 := \frac{1}{1+\beta} = \frac{\nu}{\sigma - \lambda_0 + \mu + \nu}.$$
(16)

When we are considering a constant treatment, c(t) = c, we will write  $\sigma(c)$  and  $f_0(c)$  to explicitly denote the dependence on the dose c. For detailed derivations of the above formulas, we refer to Appendix A.2 of our previous work [14].

#### 4.6 Optimal control problem

To determine the optimal dosing strategy, we assume a finite treatment horizon [0, T] with T > 0. Let PC([0, T]) denote the set of all piecewise continuous functions on [0, T]. The space of allowable dosing strategies is

$$\mathcal{C}_T := \{ c \in \mathrm{PC}([0,T]) : c(t) \le c_{\max}, \forall t \in [0,T] \},\$$

where  $c_{\text{max}}$  is the maximum allowable instantaneous dose. For simplicity, when deriving optimal dosing strategies, we assume that the drug dose corresponds perfectly to the drug concentration reaching the tumor, thereby ignoring pharmacokinetic effects. Our main objective is to find the dosing strategy  $c \in C_T$  which minimizes the expected tumor size at the end of the treatment period. More specifically, we aim to solve the optimal control problem

$$\inf_{c \in \mathcal{C}_T} n(T) = \inf_{c \in \mathcal{C}_T} (n_0(T) + n_1(T)).$$

By (13) and (14), it is equivalent to solve the problem

$$\inf_{c \in \mathcal{C}_T} \int_0^T u(c, f_0) dt, \tag{17}$$

where  $u(c, f_0) := (\lambda_0(c) - \lambda_1)f_0 + \lambda_1$  is the instantaneous growth rate of the population and  $f_0(t)$  is governed by the differential equation

$$\frac{df_0}{dt} = \left(\lambda_1 - \lambda_0(c)\right) f_0^2 - \left(\lambda_1 - \lambda_0(c) + \mu(c) + \nu(c)\right) f_0 + \nu(c)$$

Note that under the assumption that c is piecewise continuous on [0, T],  $f_0$  is piecewise continuously differentiable on [0, T]. Over a finite treatment horizon [0, T], the average growth rate of the population is given by

$$\bar{u}_T(c) = \frac{1}{T} \int_0^T u(c, f_0) dt.$$

In our investigation of the optimal control problem (17), we will be interested in knowing which treatment is the best in the long run as  $T \to \infty$ . Since the integral in (17) can be unbounded as  $T \to \infty$ , we will also consider the *long-run average growth rate* 

$$\bar{u}_{\infty}(c) = \limsup_{T \to \infty} \bar{u}_T(c) = \limsup_{T \to \infty} \frac{1}{T} \int_0^T u(c, f_0) dt,$$
(18)

where  $c: [0, \infty) \to [0, c_{\max}]$  is considered a treatment with an infinite time horizon.

## 4.7 Rapid pulsed strategies

Pulsed schedules are simple treatment strategies which alternate between giving a fixed drug dose and no drug. We identify a pulsed schedule as a three-dimensional vector  $(c, t_{cycle}, \varphi)$ where c is the dose applied,  $t_{cycle}$  is the duration of each treatment cycle, and  $\varphi$  is the proportion of drug application during each cycle. We will be particularly interested in idealized strategies where the treatment cycles are arbitrarily short. We note that if the cycle time  $t_{cycle} = dt$  is infinitesimal, then using (11), the infinitesimal change in  $f_0$  is

$$df_{0} = \varphi dt ((\lambda_{1} - \lambda_{0}(c)) f_{0}^{2} - (\lambda_{1} - \lambda_{0}(c) + \mu(c) + \nu(c)) f_{0} + \nu(c)) + (1 - \varphi) dt ((\lambda_{1} - \lambda_{0}) f_{0}^{2} - (\lambda_{1} - \lambda_{0} + \mu_{0} + \nu_{0}) f_{0} + \nu_{0}).$$

If we define the average rates over each cycle,

$$\lambda_0(c,\varphi) := \varphi \lambda_0(c) + (1-\varphi)\lambda_0 = \lambda_0 + \varphi(\lambda_0(c) - \lambda_0),$$
  

$$\bar{\mu}(c,\varphi) := \varphi \mu(c) + (1-\varphi)\mu_0 = \mu_0 + \varphi(\mu(c) - \mu_0),$$
  

$$\bar{\nu}(c,\varphi) := \varphi \nu(c) + (1-\varphi)\nu_0 = \nu_0 + \varphi(\nu(c) - \nu_0),$$
  
(19)

then  $f_0(t)$  obeys the differential equation

$$\frac{df_0}{dt} = \left(\lambda_1 - \bar{\lambda}_0(c,\varphi)\right) f_0^2 - \left(\lambda_1 - \bar{\lambda}_0(c,\varphi) + \bar{\mu}(c,\varphi) + \bar{\nu}(c,\varphi)\right) f_0 + \bar{\nu}(c,\varphi).$$
(20)

Similarly, the instantaneous growth rate of the population is given by

$$\bar{u}(c,\varphi,f_0) = (\bar{\lambda}_0(c,\varphi) - \lambda_1)f_0 + \lambda_1.$$

Thus, under an arbitrarily fast pulsed schedule, the associated model dynamics can be approximated by a constant-dose model with parameters  $\bar{\lambda}_0(c,\varphi)$ ,  $\lambda_1$ ,  $\bar{\mu}(c,\varphi)$  and  $\bar{\nu}(c,\varphi)$ . By Section 4.5, in the long run, the population grows at exponential rate

$$\sigma(c,\varphi) := \frac{1}{2} \Big( (\bar{\lambda}_0(c,\varphi) - \bar{\mu}(c,\varphi)) + (\lambda_1 - \bar{\nu}(c,\varphi)) \\ + \sqrt{((\bar{\lambda}_0(c,\varphi) - \bar{\mu}(c,\varphi)) - (\lambda_1 - \bar{\nu}(c,\varphi)))^2 + 4\bar{\mu}(c,\varphi)\bar{\nu}(c,\varphi)} \Big).$$
(21)

In addition, the population eventually reaches an equilibrium composition, where the proportion of sensitive cells becomes

$$\bar{f}_0(c,\varphi) := \frac{\bar{\nu}(c,\varphi)}{\sigma(c,\varphi) - \bar{\lambda}_0(c,\varphi) + \bar{\mu}(c,\varphi) + \bar{\nu}(c,\varphi)}.$$
(22)

## 4.8 Baseline parameters

Our computational results are shown using a parametrization of the model inspired by experimental investigations of drug tolerance in cancer and bacteria. The parameter values are shown in Table 1. First, we assume that in the absence of drug, the proliferation rate of sensitive cells is  $\lambda_0 = 0.04$ , and that the maximal drug effect on the death rate is  $\Delta d_0 = 0.08$ . Our motivating example is PC9 cells treated with a large dose of erlotinib, for which the proliferation rate of sensitive cells in the absence of drug has been estimated as  $\lambda_0 = 0.04$  per hour and the drug effect as  $\Delta d_0 = 0.08$  per hour [14]. We note that for a cohort of patients with metastatic melanoma treated with vemurafenib, the typical value of  $\lambda_0$  was 0.01 per day and the typical drug effect was  $\Delta d_0 = 0.04$  per day. Thus, the time unit for the baseline regime can be considered to be hours in the *in vitro* setting and days in the clinical setting.

Second, we assume that in the absence of drug,  $\lambda_1 \ll \lambda_0$ , meaning that the drug-tolerant cells proliferate much slower than the drug-sensitive cells, and that they only make up a small proportion of the tumor at the start of the treatment. This is consistent with experimental evidence showing that drug-tolerant cells are generally slow-cycling [7, 52, 15, 53, 10, 11]. Third, we assume that  $\mu_0 \ll \lambda_0$ , meaning that transitions from sensitivity to tolerance are rare compared to cell divisions. This is consistent with evidence that epigenetic modifications are commonly retained for  $10 - 10^5$  cell divisions [54, 55, 56]. Fourth, we assume that  $\nu_0$  is significantly larger than  $\mu_0$ , meaning that the tolerant state is lost faster than it is adopted. This is consistent with experimental evidence both from cancer [57, 58] and bacteria [59].

In Figures 2, 3 and 4, we assume that k = m = 0.0004 and that the maximum allowable dose is  $c_{\text{max}} = 10$  as a proportion of the  $\text{EC}_{50}^d$  dose. In Figures 5 and 6, we assume that  $\Delta \mu = 0.004$ ,  $\Delta \nu = 0.003$  and  $c_{\text{max}} = 10$ .

We note that with this parametrization, the net growth rate of tolerant cells taking phenotypic switching into account is  $\lambda_1 - \nu_0 = -0.003 < 0$ . Thus, in the presence of drug, the tolerant population decays over time, but much slower than the sensitive cells.

Parameter	$\lambda_0$	$\Delta d_0$	$\lambda_1$	$\mu_0$	$\nu_0$	k	m	$\Delta \mu$	$\Delta \nu$	$c_{\max}$
Value	0.04	0.08	0.001	0.0004	0.004	0.0004	0.0004	0.004	0.003	10

Table 1: Baseline parameter values used in the study.

## References

- [1] Lauren MF Merlo, John W Pepper, Brian J Reid, and Carlo C Maley. Cancer as an evolutionary and ecological process. *Nature reviews cancer*, 6(12):924, 2006.
- [2] Mel Greaves. Evolutionary determinants of cancer. Cancer Discovery, 5(8):806-820, 2015.
- [3] William A Flavahan, Elizabeth Gaskell, and Bradley E Bernstein. Epigenetic plasticity and the hallmarks of cancer. *Science*, 357(6348):eaal2380, 2017.
- [4] Peter A Jones and Stephen B Baylin. The epigenomics of cancer. Cell, 128(4):683–692, 2007.

- [5] Amy Brock, Hannah Chang, and Sui Huang. Non-genetic heterogeneity a mutationindependent driving force for the somatic evolution of tumours. *Nature Reviews Genetics*, 10(5):336, 2009.
- [6] Robert Brown and Gordon Strathdee. Epigenomics and epigenetic therapy of cancer. Trends in molecular medicine, 8(4):S43–S48, 2002.
- [7] Sreenath V Sharma, Diana Y Lee, Bihua Li, Margaret P Quinlan, Fumiyuki Takahashi, Shyamala Maheswaran, Ultan McDermott, Nancy Azizian, Lee Zou, Michael A Fischbach, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. *Cell*, 141(1):69–80, 2010.
- [8] Aaron Goldman, Biswanath Majumder, Andrew Dhawan, Sudharshan Ravi, David Goldman, Mohammad Kohandel, Pradip K Majumder, and Shiladitya Sengupta. Temporally sequenced anticancer drugs overcome adaptive resistance by targeting a vulnerable chemotherapy-induced phenotypic transition. *Nature communications*, 6:6139, 2015.
- [9] Michael Ramirez, Satwik Rajaram, Robert J Steininger, Daria Osipchuk, Maike A Roth, Leanna S Morinishi, Louise Evans, Weiyue Ji, Chien-Hsiang Hsu, Kevin Thurley, et al. Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells. *Nature communications*, 7:10690, 2016.
- [10] Aaron N Hata, Matthew J Niederst, Hannah L Archibald, Maria Gomez-Caraballo, Faria M Siddiqui, et al. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. *Nature Medicine*, 22(3):262–269, 2016.
- [11] Sydney M Shaffer, Margaret C Dunagin, Stefan R Torborg, Eduardo A Torre, Benjamin Emert, Clemens Krepler, Marilda Beqiri, Katrin Sproesser, Patricia A Brafford, Min Xiao, et al. Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance. *Nature*, 546(7658):431, 2017.
- [12] Yapeng Su, Wei Wei, Lidia Robert, Min Xue, Jennifer Tsoi, Angel Garcia-Diaz, Blanca Homet Moreno, Jungwoo Kim, Rachel H Ng, Jihoon W Lee, et al. Singlecell analysis resolves the cell state transition and signaling dynamics associated with melanoma drug-induced resistance. *Proceedings of the National Academy of Sciences*, 114(52):13679–13684, 2017.
- [13] Cyril Neftel, Julie Laffy, Mariella G Filbin, Toshiro Hara, Marni E Shore, Gilbert J Rahme, Alyssa R Richman, Dana Silverbush, McKenzie L Shaw, Christine M Hebert, et al. An integrative model of cellular states, plasticity, and genetics for glioblastoma. *Cell*, 178(4):835–849, 2019.
- [14] Einar Bjarki Gunnarsson, Subhajyoti De, Kevin Leder, and Jasmine Foo. Understanding the role of phenotypic switching in cancer drug resistance. *Journal of Theoretical Biology*, 490:110162, 2020.
- [15] Angela Oliveira Pisco, Amy Brock, Joseph Zhou, Andreas Moor, Mitra Mojtahedi, Dean Jackson, and Sui Huang. Non-darwinian dynamics in therapy-induced cancer drug resistance. *Nature communications*, 4:2467, 2013.

- [16] Mohammad Fallahi-Sichani, Verena Becker, Benjamin Izar, Gregory J Baker, Jia-Ren Lin, Sarah A Boswell, Parin Shah, Asaf Rotem, Levi A Garraway, and Peter K Sorger. Adaptive resistance of melanoma cells to raf inhibition via reversible induction of a slowly dividing de-differentiated state. *Molecular systems biology*, 13(1):905, 2017.
- [17] Kavya Vipparthi, Kishore Hari, Priyanka Chakraborty, Subhashis Ghosh, Ankit Kumar Patel, Arnab Ghosh, Nidhan Kumar Biswas, Rajeev Sharan, Pattatheyil Arun, Mohit Kumar Jolly, et al. Emergence of hybrid states of stem-like cancer cells correlates with poor prognosis in oral cancer. *Iscience*, 25(5), 2022.
- [18] Mariangela Russo, Simone Pompei, Alberto Sogari, Mattia Corigliano, Giovanni Crisafulli, Alberto Puliafito, Simona Lamba, Jessica Erriquez, Andrea Bertotti, Marco Gherardi, et al. A modified fluctuation-test framework characterizes the population dynamics and mutation rate of colorectal cancer persister cells. *Nature Genetics*, 54(7):976–984, 2022.
- [19] Bernadett Szikriszt, Ádám Póti, Orsolya Pipek, Marcin Krzystanek, Nnennaya Kanu, János Molnár, Dezső Ribli, Zoltán Szeltner, Gábor E Tusnády, István Csabai, et al. A comprehensive survey of the mutagenic impact of common cancer cytotoxics. *Genome Biology*, 17(1):1–16, 2016.
- [20] Subramanian Venkatesan, Charles Swanton, Barry S Taylor, and Joseph F Costello. Treatment-induced mutagenesis and selective pressures sculpt cancer evolution. *Cold Spring Harbor Perspectives in Medicine*, 7(8):a026617, 2017.
- [21] Devon M Fitzgerald, PJ Hastings, and Susan M Rosenberg. Stress-induced mutagenesis: implications in cancer and drug resistance. Annual review of cancer biology, 1(1):119– 140, 2017.
- [22] Mariangela Russo, Giovanni Crisafulli, Alberto Sogari, Nicole M Reilly, Sabrina Arena, Simona Lamba, Alice Bartolini, Vito Amodio, Alessandro Magrì, Luca Novara, et al. Adaptive mutability of colorectal cancers in response to targeted therapies. *Science*, 366(6472):1473–1480, 2019.
- [23] Arcadi Cipponi, David L Goode, Justin Bedo, Mark J McCabe, Marina Pajic, David R Croucher, Alvaro Gonzalez Rajal, Simon R Junankar, Darren N Saunders, Pavel Lobachevsky, et al. Mtor signaling orchestrates stress-induced mutagenesis, facilitating adaptive evolution in cancer. *Science*, 368(6495):1127–1131, 2020.
- [24] Robert S Kerbel and Barton A Kamen. The anti-angiogenic basis of metronomic chemotherapy. *Nature Reviews Cancer*, 4(6):423–436, 2004.
- [25] Sébastien Benzekry, Eddy Pasquier, Dominique Barbolosi, Bruno Lacarelle, Fabrice Barlési, Nicolas André, and Joseph Ciccolini. Metronomic reloaded: Theoretical models bringing chemotherapy into the era of precision medicine. In *Seminars in Cancer Biology*, volume 35, pages 53–61. Elsevier, 2015.
- [26] Larry Norton. The Norton-Simon hypothesis revisited. *Cancer Treatment Reports*, 70(1):163–169, 1986.

- [27] Robert Brown, Edward Curry, Luca Magnani, Charlotte S Wilhelm-Benartzi, and Jane Borley. Poised epigenetic states and acquired drug resistance in cancer. *Nature Reviews Cancer*, 14(11):747, 2014.
- [28] James M Greene, Jana L Gevertz, and Eduardo D Sontag. Mathematical approach to differentiate spontaneous and induced evolution to drug resistance during cancer treatment. JCO clinical cancer informatics, 3:1–20, 2019.
- [29] Andrei R Akhmetzhanov, Jong Wook Kim, Ryan Sullivan, Robert A Beckman, Pablo Tamayo, and Chen-Hsiang Yeang. Modelling bistable tumour population dynamics to design effective treatment strategies. *Journal of theoretical biology*, 474:88–102, 2019.
- [30] James M Greene, Cynthia Sanchez-Tapia, and Eduardo D Sontag. Mathematical details on a cancer resistance model. Frontiers in Bioengineering and Biotechnology, 8:501, 2020.
- [31] Teemu Kuosmanen, Johannes Cairns, Robert Noble, Niko Beerenwinkel, Tommi Mononen, and Ville Mustonen. Drug-induced resistance evolution necessitates less aggressive treatment. *PLoS Computational Biology*, 17(9):e1009418, 2021.
- [32] Erin Angelini, Yue Wang, Joseph Xu Zhou, Hong Qian, and Sui Huang. A model for the intrinsic limit of cancer therapy: Duality of treatment-induced cell death and treatment-induced stemness. *PLOS Computational Biology*, 18(7):e1010319, 2022.
- [33] Mattia Corigliano, Arianna Di Bernardo, Marco Cosentino Lagomarsino, and Simone Pompei. Optimal treatment for drug-induced cancer persisters involves release periods and intermediate drug doses. *bioRxiv*, pages 2024–11, 2024.
- [34] Manel Esteller. Cpg island hypermethylation and tumor suppressor genes: a booming present, a brighter future. *Oncogene*, 21(35):5427–5440, 2002.
- [35] Susana Romero-Garcia, Heriberto Prado-Garcia, and Angeles Carlos-Reyes. Role of dna methylation in the resistance to therapy in solid tumors. *Frontiers in oncology*, 10:1152, 2020.
- [36] Lingyue Gao, Zhuo-Xun Wu, Yehuda G Assaraf, Zhe-Sheng Chen, and Lihui Wang. Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function. Drug Resistance Updates, 57:100770, 2021.
- [37] Masaki Okano, Daphne W Bell, Daniel A Haber, and En Li. Dna methyltransferases dnmt3a and dnmt3b are essential for de novo methylation and mammalian development. *Cell*, 99(3):247–257, 1999.
- [38] Andrea Hermann, Rachna Goyal, and Albert Jeltsch. The dnmt1 dna-(cytosine-c5)methyltransferase methylates dna processively with high preference for hemimethylated target sites. *Journal of Biological Chemistry*, 279(46):48350–48359, 2004.
- [39] Manel Esteller. Epigenetics in cancer. New England Journal of Medicine, 358(11):1148– 1159, 2008.

- [40] Sylvain Goutelle, Michel Maurin, Florent Rougier, Xavier Barbaut, Laurent Bourguignon, Michel Ducher, and Pascal Maire. The hill equation: a review of its capabilities in pharmacological modelling. *Fundamental & Clinical Pharmacology*, 22(6):633–648, 2008.
- [41] Pramod R. Somvanshi and Kareenhalli V. Venkatesh. *Hill Equation*, pages 892–895. Springer New York, New York, NY, 2013.
- [42] Robert A Gatenby. A change of strategy in the war on cancer. Nature, 459(7246):508– 509, 2009.
- [43] Chenyu Wu, Einar Bjarki Gunnarsson, Jasmine Foo, and Kevin Leder. Inferring druginduced plasticity via drug screen data. arXiv preprint arXiv:2409.18879, 2024.
- [44] Einar Bjarki Gunnarsson, Jasmine Foo, and Kevin Leder. Statistical inference of the rates of cell proliferation and phenotypic switching in cancer. *Journal of Theoretical Biology*, 568:111497, 2023.
- [45] Mary F McGuire, Heiko Enderling, Dorothy I Wallace, Jaspreet Batra, Marie Jordan, Sushil Kumar, John C Panetta, and Eddy Pasquier. Formalizing an integrative, multidisciplinary cancer therapy discovery workflow. *Cancer research*, 73(20):6111–6117, 2013.
- [46] Franziska Michor and Kathryn Beal. Improving cancer treatment via mathematical modeling: surmounting the challenges is worth the effort. *Cell*, 163(5):1059–1063, 2015.
- [47] Sara Hamis, Gibin G Powathil, and Mark AJ Chaplain. Blackboard to bedside: a mathematical modeling bottom-up approach toward personalized cancer treatments. JCO clinical cancer informatics, 3:1–11, 2019.
- [48] Einar Bjarki Gunnarsson and Jasmine Foo. Mathematical models of resistance evolution under continuous and pulsed anti-cancer therapies. In Mohit Kumar Jolly and Prakash Kulkarni, editors, *Cancer Systems Biology and Translational Mathematical Oncology*. Oxford University Press, 2025.
- [49] Tyler Cassidy, Daniel Nichol, Mark Robertson-Tessi, Morgan Craig, and Alexander RA Anderson. The role of memory in non-genetic inheritance and its impact on cancer treatment resistance. *PLoS Computational Biology*, 17(8):e1009348, 2021.
- [50] Morgan Craig, Kamran Kaveh, Alec Woosley, Andrew S Brown, David Goldman, Elliot Eton, Ravindra M Mehta, Andrew Dhawan, Kazuya Arai, M Mamunur Rahman, et al. Cooperative adaptation to therapy (cat) confers resistance in heterogeneous non-small cell lung cancer. *PLoS computational biology*, 15(8), 2019.
- [51] Krishna B Athreya and Peter E Ney. *Branching processes*. Courier Corporation, 2004.
- [52] Alexander Roesch, Mizuho Fukunaga-Kalabis, Elizabeth C Schmidt, Susan E Zabierowski, Patricia A Brafford, Adina Vultur, Devraj Basu, Phyllis Gimotty, Thomas Vogt, and Meenhard Herlyn. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. *Cell*, 141(4):583–594, 2010.

- [53] Alexander Roesch, Adina Vultur, Ivan Bogeski, Huan Wang, Katharina M Zimmermann, David Speicher, Christina Körbel, Matthias W Laschke, Phyllis A Gimotty, Stephan E Philipp, et al. Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling jarid1bhigh cells. *Cancer cell*, 23(6):811– 825, 2013.
- [54] Mario Niepel, Sabrina L Spencer, and Peter K Sorger. Non-genetic cell-to-cell variability and the consequences for pharmacology. *Current opinion in chemical biology*, 13(5-6):556–561, 2009.
- [55] Alex Sigal, Ron Milo, Ariel Cohen, Naama Geva-Zatorsky, Yael Klein, Yuvalal Liron, Nitzan Rosenfeld, Tamar Danon, Natalie Perzov, and Uri Alon. Variability and memory of protein levels in human cells. *Nature*, 444(7119):643, 2006.
- [56] Ariel A Cohen, Naama Geva-Zatorsky, Eran Eden, Milana Frenkel-Morgenstern, Iirina Issaeva, Alex Sigal, Ron Milo, Cellina Cohen-Saidon, Yuvalal Liron, Zvi Kam, et al. Dynamic proteomics of individual cancer cells in response to a drug. *science*, 322(5907):1511–1516, 2008.
- [57] Piyush B Gupta, Christine M Fillmore, Guozhi Jiang, Sagi D Shapira, Kai Tao, Charlotte Kuperwasser, and Eric S Lander. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. *Cell*, 146(4):633–644, 2011.
- [58] Sasan Paryad-Zanjani, Michael M Saint-Antoine, and Abhyudai Singh. Optimal scheduling of therapy to delay cancer drug resistance. *IFAC-PapersOnLine*, 54(15):239–244, 2021.
- [59] Thomas M Norman, Nathan D Lord, Johan Paulsson, and Richard Losick. Stochastic switching of cell fate in microbes. Annual review of microbiology, 69:381–403, 2015.
- [60] Michael McAsey, Libin Mou, and Weimin Han. Convergence of the forward-backward sweep method in optimal control. *Computational Optimization and Applications*, 53:207– 226, 2012.
- [61] Jesse A Sharp. Numerical methods for optimal control and parameter estimation in the life sciences. PhD thesis, Queensland University of Technology, 2022.

## S1 Supplementary text

## S1.1 Forward-backward sweep method

For the case of linear induction of tolerance, we use the forward-backward sweep method [60, 61] to solve the optimal control problem (17). The problem is

$$\min_{c \in \mathcal{C}_T} \int_0^T u(c, f_0) dt,$$

where  $u(c, f_0) := (\lambda_0(c) - \lambda_1)f_0 + \lambda_1$  is the instantaneous growth rate of the population and  $f_0(t)$  is governed by the differential equation

$$\frac{df_0}{dt} = g(f_0, c),$$

where

$$g(f_0, c) := (\lambda_1 - \lambda_0(c)) f_0^2 - (\lambda_1 - \lambda_0(c) + \mu(c) + \nu(c)) f_0 + \nu(c)$$

The so-called *Hamiltonian* for this problem is

$$\mathcal{H}(f_0, c, \gamma) = u(f_0, c) + \gamma g(f_0, c), \tag{23}$$

where  $\gamma = (\gamma(t))_{t \in [0,T]}$  is a Lagrangian multiplier function. By Pontryagin's principle, the optimal solution  $c^* = (c^*(t))_{t \in [0,T]}$  must satisfy

$$c^*(t) = \operatorname{argmin}_c \mathcal{H}(f_0, c, \gamma)$$

for each  $t \in [0,T]$ , where  $f_0 = (f_0(t))_{t \in [0,T]}$  and  $(\gamma(t))_{t \in [0,T]}$  satisfy the differential equations

$$\frac{\partial \mathcal{H}}{\partial \gamma} = f'_0,$$
$$\frac{\partial \mathcal{H}}{\partial f_0} = -\gamma'.$$

The boundary conditions are  $f_0(0) = \alpha$  for some fixed  $\alpha \in [0,1]$  and  $\gamma(T) = 0$ . For our problem, the two differential equations above become

$$f_0' = (\lambda_1 - \lambda_0(c))f_0^2 - (\lambda_1 - \lambda_0(c) + \mu(c) + \nu(c))f_0 + \nu(c), \quad f_0(0) = \alpha,$$
(24)

$$\gamma' = -(2(\lambda_1 - \lambda_0(c))f_0 - (\lambda_1 - \lambda_0(c) + \mu(c) + \nu(c)))\gamma - (\lambda_0(c) - \lambda_1), \quad \gamma(T) = 0.$$
(25)

To compute the optimal solution, we apply the forward-backward sweep method, which is an iterative procedure that proceeds as follows:

- (1) We discretize time and consider a set of time points  $\mathcal{T} = [0, t_1, t_2, \dots, T]$ .
- (2) We make an initial guess for the optimal policy  $(c(t))_{t \in \mathcal{T}}$ . We simply use c(t) = 0 for all  $t \in \mathcal{T}$ .
- (3) We solve (24) using the initial condition  $f_0(0) = \alpha$ , assuming the initial guess for  $(c(t))_{t \in \mathcal{T}}$ .
- (4) We solve (25) backwards in time using the initial condition  $\gamma(T) = 0$ , assuming the initial guess for  $(c(t))_{t \in \mathcal{T}}$  and the trajectory for  $(f_0(t))_{t \in \mathcal{T}}$  from step (3).

(5) Using the obtained trajectories for  $(f_0(t))$  and  $(\gamma(t))$ , for each fixed  $t \in \mathcal{T}$  we compute the optimal dose at time t as

$$c^*(t) = \operatorname{argmax}_c \mathcal{H}(f_0, c, \gamma),$$

which boils down to solving

$$\frac{\partial \mathcal{H}}{\partial c} = 0. \tag{26}$$

For our problem, this condition can be written as a second-degree polynomial equation in c. Since

$$\begin{aligned} \frac{\partial u}{\partial c} &= f_0 \frac{\partial \lambda_0}{\partial c}, \\ \frac{\partial g}{\partial c} &= -f_0^2 \frac{\partial \lambda_0}{\partial c} + f_0 \frac{\partial \lambda_0}{\partial c} - f_0 \frac{\partial \mu}{\partial c} - f_0 \frac{\partial \nu}{\partial c} + \frac{\partial \nu}{\partial c}, \end{aligned}$$

we have

$$\begin{aligned} \frac{\partial \mathcal{H}}{\partial c} &= \frac{\partial u}{\partial c} + \gamma \frac{\partial g}{\partial c} \\ &= (f_0 - \gamma f_0^2 + \gamma f_0) \frac{\partial \lambda_0}{\partial c} - \gamma f_0 \frac{\partial \mu}{\partial c} + \gamma (1 - f_0) \frac{\partial \nu}{\partial c}. \end{aligned}$$

Now,

$$\begin{split} \lambda_0(c) &= \lambda_0 - \Delta d_0 \cdot \frac{c}{c+1} \quad \Rightarrow \quad \frac{\partial \lambda_0}{\partial c} = -\frac{\Delta d_0}{(c+1)^2}, \\ \mu(c) &= \mu_0 + kc \quad \Rightarrow \quad \frac{\partial \mu}{\partial c} = k, \\ \nu(c) &= \nu_0 - mc \quad \Rightarrow \quad \frac{\partial \nu}{\partial c} = -m. \end{split}$$

If we set

$$a(f_0, \gamma) := \Delta d_0 f_0(\gamma f_0 - 1 - \gamma), b(f_0, \gamma) := -\gamma k f_0 + \gamma m(f_0 - 1),$$

we then have

$$\frac{\partial \mathcal{H}}{\partial c} = \frac{a}{(c+1)^2} + b,$$

and we obtain the second-degree polynomial equation

$$bc^2 + 2bc + (a+b) = 0.$$

## S1.2 Mathematical analysis of optimal long-run treatment

In this section, we wish to prove two claims made in the main text:

- For linear induction of tolerance, it is optimal in the long run to apply the dose which minimizes the equilibrium growth rate  $\sigma(c)$  under a constant dose c.
- For uniformly induced tolerance, arbitrarily fast alternation between the maximum dose  $c_{\max}$  and no dose minimizes the long-run average growth rate.

We do this in several steps in the following four subsections.

## S1.2.1 Constant-parameter models

We begin by establishing a simple and intuitive lemma saying that a lower proliferation potential for drug-sensitive cells implies a lower equilibrium growth rate. In addition, we establish a lower bound on the equilibrium growth rate. In what follows, we will let  $M(\lambda_0, \lambda_1, \mu, \nu)$ denote the constant-parameter model with parameters  $\lambda_0$ ,  $\lambda_1$ ,  $\mu$  and  $\nu$ .

**Lemma 1.** In the constant-parameter model  $M(\lambda_0, \lambda_1, \mu, \nu)$ , the equilibrium growth rate  $\sigma = \sigma(\lambda_0, \lambda_1, \mu, \nu)$  is increasing in  $\lambda_0$  and it satisfies  $\sigma > \lambda_1 - \nu$ .

*Proof.* The equilibrium growth rate is given by the expression

$$\sigma = \frac{1}{2} \left( (\lambda_0 - \mu) + (\lambda_1 - \nu) + \sqrt{((\lambda_0 - \mu) - (\lambda_1 - \nu))^2 + 4\mu\nu} \right).$$

Consider the function

$$f(x) := \frac{1}{2} \left( x - a + \sqrt{(x - b)^2 + c} \right), \quad x \in \mathbb{R},$$

where

$$a := \mu - \lambda_1 + \nu, \quad b := \mu + \lambda_1 - \nu, \quad c := 4\mu\nu.$$

The derivative of this function is

$$f'(x) = \frac{1}{2} \left( 1 + \frac{x-b}{\sqrt{(x-b)^2 + c}} \right), \quad x \in \mathbb{R}.$$

Since we assume  $\mu, \nu > 0$  (Sections 4.1 and 4.3), we have

$$|x-b| < \sqrt{(x-b)^2 + c},$$

which implies that f'(x) > 0 for all  $x \in \mathbb{R}$  and f is therefore strictly increasing. Since also

$$\lim_{x \to -\infty} f(x) = \frac{1}{2}(b-a) = \lambda_1 - \nu,$$

we can conclude that  $\sigma > \lambda_1 - \nu$ .

We next establish a simple lemma relating the equilibrium growth rate of a constantparameter model to the instantaneous growth rate  $u(c, f_0) = (\lambda_0 - \lambda_1)f_0 + \lambda_1$ .

**Lemma 2.** Let  $M(\lambda_0, \lambda_1, \mu, \nu)$  be a constant-parameter model with equilibrium growth rate  $\sigma = \sigma(\lambda_0, \lambda_1, \mu, \nu)$  and equilibrium proportion of sensitive cells  $\bar{f}_0 = \bar{f}_0(\lambda_0, \lambda_1, \mu, \nu)$ . Then

$$(\lambda_0 - \lambda_1)f_0 + \lambda_1 = \sigma.$$

Proof. If the model is started in equilibrium, meaning that  $n_0(0) = N\bar{f}_0$  and  $n_1(0) = N(1 - \bar{f}_0)$  for some N > 0, the population grows exponentially at rate  $\sigma$  from the start and the proportion of sensitive cells remains fixed at  $\bar{f}_0$  throughout. This can be verified by consulting the explicit expression provided in Section 4.5 of the main text. However, in expression (12), we showed that in general, if the current proportion of sensitive cells is  $f_0$ , the instantaneous growth rate is  $(\lambda_0 - \lambda_1)f_0 + \lambda_1$ . Thus, we must have  $(\lambda_0 - \lambda_1)\bar{f}_0 + \lambda_1 = \sigma$ .

## S1.2.2 Supporting results for general dosing functions $\lambda_0(c)$ , $\mu(c)$ and $\nu(c)$

We next establish two supporting lemmas which hold for arbitrary functions  $\lambda_0(c)$ ,  $\mu(c)$  and  $\nu(c)$  that are integrable on every finite interval [0, T]. We additionally assume that  $\lambda_0(c)$  is decreasing in c with  $\lambda_0(0) = \lambda_0$  and that  $\mu(c)$  and  $\nu(c)$  are bounded by  $\mu_0 \leq \mu(c) \leq \mu_{\max}$  and  $\nu_{\min} \leq \nu(c) \leq \nu_0$  for  $c \in [0, c_{\max}]$  with  $\mu_0, \nu_{\min} > 0$ .

Before proceeding, we need to define a few terms. For a given infinite-horizon treatment  $c : [0, \infty) \to [0, c_{\max}]$ , we define a *treatment segment* to be the restriction  $c|_I : I \to [0, c_{\max}]$  of c to I, where  $I \subseteq [0, \infty)$  can be written as a finite disjoint union of closed intervals

$$I = \bigcup_{i=1}^{n} [a_i, b_i]$$

with  $a_i \leq b_i$  for all  $i = 1, \ldots, n$ , and

$$f_0(b_i) = f_0(a_{i+1}), \quad i = 1, \dots, n-1.$$
 (27)

In other words,  $c|_I$  is a treatment on the bounded set I which starts with the sensitive cell proportion  $f_0(a_1)$ . We also define the average growth rate of the segment,

$$\bar{u}_I(c) = \frac{1}{|I|} \int_I \left( (\lambda_0(c) - \lambda_1) f_0 + \lambda_1 \right) dt,$$

where |I| is the total length of the intervals that comprise I (the Lebesgue measure of I). We say that the treatment segment is  $\varepsilon$ -stable if

$$\sup_{x,y\in I} |f_0(x) - f_0(y)| \le \varepsilon.$$
(28)

We now show that if a treatment segment is  $\varepsilon$ -stable, its average growth rate can be approximated by the equilibrium growth rate of a constant-parameter model. The constant parameters are obtained by taking averages of the model parameters over the segment.

**Lemma 3.** Let  $\varepsilon > 0$  and let  $c|_I : I \to [0, c_{\max}]$  be an  $\varepsilon$ -stable treatment segment with length  $|I| \ge 1$  and average growth rate  $\bar{u}_I(c)$ . Let  $\bar{\lambda}_0(I)$ ,  $\bar{\mu}(I)$  and  $\bar{\nu}(I)$  denote the average values of the respective parameters over I:

$$\bar{\lambda}_0(I) = \frac{1}{|I|} \int_I \lambda_0(c) dt, \quad \bar{\mu}(I) = \frac{1}{|I|} \int_I \mu(c) dt, \quad \bar{\nu}(I) = \frac{1}{|I|} \int_I \nu(c) dt,$$

and let  $\sigma = \sigma(\bar{\lambda}_0(I), \lambda_1, \bar{\mu}(I), \bar{\nu}(I))$  denote the equilibrium growth rate of the constant-parameter model  $M(\bar{\lambda}_0(I), \lambda_1, \bar{\mu}(I), \bar{\nu}(I))$ . Then, there exist constants C, D > 0 which only depend on  $\lambda_0, \lambda_1, \mu_0, \mu_{\max}, \nu_0$  and  $\nu_{\min}$  so that

$$\varepsilon \leq C \quad \Rightarrow \quad \sigma \leq \bar{u}_I(c) + D\varepsilon.$$

*Proof.* Write  $I = \bigcup_{i=1}^{n} [a_i, b_i]$  and let  $g := f_0(a_1)$  be the starting proportion of sensitive cells on the treatment segment. Set

$$\alpha(c) := \lambda_1 - \lambda_0(c), \quad \beta(c) := -\lambda_1 + \lambda_0(c) - \mu(c) - \nu(c).$$

By (11), we have that

$$f_0' = \alpha(c)f_0^2 + \beta(c)f_0 + \nu(c),$$

which implies by (27),

$$\left| \int_{I} \left( \alpha(c) f_{0}^{2} + \beta(c) f_{0} + \nu(c) \right) dt \right| = \left| \sum_{i=1}^{n} (f_{0}(b_{i}) - f_{0}(a_{i})) \right| = |f(b_{n}) - f(a_{1})| \le \varepsilon.$$
(29)

Now, let

$$\bar{\alpha}(I) := \frac{1}{|I|} \int_{I} \alpha(c) dt, \quad \bar{\beta}(I) := \frac{1}{|I|} \int_{I} \beta(c) dt,$$

be the averages values of  $\alpha(c)$  and  $\beta(c)$  over I, where we note that

$$\frac{1}{|I|} \int_{I} |\bar{\alpha}(c)| \leq \lambda_0 + \lambda_1, \quad \frac{1}{|I|} \int_{I} |\bar{\beta}(c)| \leq \lambda_0 + \lambda_1 + \mu_{\max} + \nu_0.$$

In what follows, we write  $\bar{\alpha} = \bar{\alpha}(I)$ ,  $\bar{\beta} = \bar{\beta}(I)$  and  $\bar{\nu} = \bar{\nu}(I)$  for ease of notation. Note that

$$\begin{split} \bar{\alpha}g^2 + \bar{\beta}g + \bar{\nu} \\ = & \frac{1}{|I|} \int_I \left( \alpha(c)g^2 + \beta(c)g + \nu(c) \right) dt \\ = & \frac{1}{|I|} \int_I \left( \alpha(c)f_0^2 + \beta(c)f_0 + \nu(c) \right) dt + \frac{1}{|I|} \int_I \left( \alpha(c)(g^2 - f_0^2) + \beta(c)(g - f_0) \right) dt, \end{split}$$

which implies by (29), the fact that  $c|_I$  is  $\varepsilon$ -stable and the assumption  $|I| \ge 1$ ,

$$\left|\bar{\alpha}g^2 + \bar{\beta}g + \bar{\nu}\right| \le \frac{\varepsilon}{|I|} + \varepsilon \left(\frac{2}{|I|} \int_I |\bar{\alpha}(c)| + \frac{1}{|I|} \int_I |\bar{\beta}(c)|\right) \le C_1 \varepsilon, \tag{30}$$

where  $C_1 := 1 + 3(\lambda_0 + \lambda_1) + \mu_{\max} + \nu_0 > 0$ . Now, let  $\bar{f}_0 = \bar{f}_0(\bar{\lambda}_0(I), \lambda_1, \bar{\mu}(I), \bar{\nu}(I))$  be the equilibrium proportion of sensitive cells under the constant-parameter model  $M(\bar{\lambda}_0(I), \lambda_1, \bar{\mu}(I), \bar{\nu}(I))$ . By Lemma 2,

$$\sigma = (\bar{\lambda}_0(I) - \lambda_1)\bar{f}_0 + \lambda_1.$$

Set  $P(x) := \bar{\alpha}x^2 + \bar{\beta}x + \bar{\nu}$  and note that  $P(\bar{f}_0) = 0$ . Since  $P(0) = \bar{\nu} > 0$  and  $P(1) = -\bar{\mu} < 0$ ,  $\bar{f}_0$  is the unique root of P in [0,1]. Moreover,  $|P(g)| \leq C_1 \varepsilon$  by (30), which suggests that gand  $\bar{f}_0$  are close to each another when  $\varepsilon$  is small. In fact, by applying a linear approximation of P around  $\bar{f}_0$ , we can show that the distance between g and  $\bar{f}_0$  is of order  $\varepsilon$ . More precisely, there exist constants  $C_2, C_3 > 0$  so that if  $\varepsilon \leq C_2$ , then

$$|g - f_0| \le C_3 \varepsilon,$$

where the constants  $C_2, C_3 > 0$  only depend on  $\lambda_0, \lambda_1, \mu_0, \mu_{\text{max}}, \nu_0$  and  $\nu_{\text{min}}$ . Since this statement is intuitive and the proof involves straightforward calculations, we defer the proof to Section S1.3. Using the statement, we obtain since  $c|_I$  is  $\varepsilon$ -stable,

$$\begin{split} \bar{u}_I(c) &= \frac{1}{|I|} \int_I \left( (\lambda_0(c) - \lambda_1) f_0 + \lambda_1 \right) dt \\ &= \frac{1}{|I|} \int_I \left( (\lambda_0(c) - \lambda_1) g + \lambda_1 \right) dt + \frac{1}{|I|} \int_I (\lambda_0(c) - \lambda_1) (f_0 - g) dt \\ &= (\bar{\lambda}_0(I) - \lambda_1) g + \lambda_1 + O(\varepsilon) \\ &= (\bar{\lambda}_0(I) - \lambda_1) \bar{f}_0 + \lambda_1 + O(\varepsilon) \\ &= \sigma + O(\varepsilon), \end{split}$$

which is sufficient to prove the result.

We next show that for any treatment  $c : [0, \infty) \to [0, c_{\max}]$  satisfying a certain regularity condition, we can find an  $\varepsilon$ -stable treatment segment  $c|_I$  with approximately the same average growth rate as the long-run average growth rate of c. The regularity condition is imposed to exclude treatments that make infinitely many dose changes over a finite time interval. The condition is for example satisfied if there exists a  $\delta > 0$  so that each selected dose is given for at least  $\delta$  time units, which is a reasonable condition in practice.

**Lemma 4.** Let  $c : [0, \infty) \to [0, c_{\max}]$  be an infinite-horizon treatment so that the associated sensitive cell proportion trajectory satisfies the following regularity condition:

For each closed interval  $[d, e] \subseteq [0, 1]$  and each  $T \ge 0$ ,  $f_0^{-1}([d, e]) \cap [0, T]$  is a finite union of disjoint closed intervals  $[a_i, b_i]$  where possibly  $a_i = b_i$ . (A)

Then, for each  $\varepsilon > 0$ , there exists an  $\varepsilon$ -stable treatment segment  $c|_I$  so that

$$|I| \ge 1$$
 and  $\bar{u}_I(c) \le \bar{u}_\infty(c) + \varepsilon$ .

*Proof.* We begin by selecting  $d_0, d_1, d_2, \ldots, d_n \in [0, 1]$  so that  $d_0 = 0, d_n = 1$  and  $0 < d_k - d_{k-1} \leq \varepsilon$  for all  $k = 1, \ldots, n$ . By assumption (A), each set  $I_k(T) := f_0^{-1}([d_{k-1}, d_k]) \cap [0, T]$  for  $k = 1, \ldots, n$  and  $T \geq 0$  is a finite union of disjoint closed intervals. Note that we can write

$$\bar{u}_T(c) = \bar{u}_{[0,T]}(c) = \sum_{k=1}^n \frac{|I_k(T)|}{T} \bar{u}_{I_k(T)}(c),$$

with the understanding that  $\frac{|I_k(T)|}{T}\bar{u}_{I_k(T)}(c) = 0$  when  $|I_k(T)| = 0$ . Now let  $K := \{k \in \{1, \ldots, n\} : |I_k(T)| \ge 1$  for some  $T > 0\}$  be the index set of the segments that eventually reach length 1. Note that  $\bar{u}_{I_k(T)}(c)$  is bounded by  $\lambda_0 + 2\lambda_1$  when  $|I_k(T)| \le 1$ . Therefore,

$$\lim_{T \to \infty} \sum_{k \in \{1,\dots,n\} \setminus K} \frac{|I_k(T)|}{T} = 0, \quad \lim_{T \to \infty} \sum_{k \in K} \frac{|I_k(T)|}{T} = 1,$$
$$\lim_{T \to \infty} \sum_{k \in \{1,\dots,n\} \setminus K} \frac{|I_k(T)|}{T} \bar{u}_{I_k(T)}(c) = 0.$$

Now let  $T_0$  be large enough so that  $|I_k(T_0)| \ge 1$  for all  $k \in K$ , and so that for any  $T \ge T_0$ ,

$$\left|\sum_{k\in\{1,\dots,n\}\setminus K} \frac{|I_k(T)|}{T} \bar{u}_{I_k(T)}(c)\right| \le \frac{\varepsilon}{2}.$$
(31)

Assume that  $\bar{u}_{I_k(T)}(c) \geq \bar{u}_{\infty}(c) + \varepsilon$  for all  $k \in K$  and  $T \geq T_0$ . Then for all  $T \geq T_0$ 

$$\sum_{k=1}^{n} \frac{|I_k(T)|}{T} \bar{u}_{I_k(T)}(c) \ge \sum_{k \in K} \frac{|I_k(T)|}{T} \bar{u}_{I_k(T)}(c) - \frac{\varepsilon}{2} \ge (\bar{u}_{\infty}(c) + \varepsilon) \sum_{k \in K} \frac{|I_k(T)|}{T} - \frac{\varepsilon}{2}$$

which leads to a contradiction when we send  $T \to \infty$ , since

$$\bar{u}_{\infty}(c) = \limsup_{T \to \infty} \bar{u}_T(c) = \limsup_{T \to \infty} \sum_{k=1}^n \frac{|I_k(T)|}{T} \bar{u}_{I_k(T)}(c).$$

Therefore, there must exist k and T so that  $|I_k(T)| \ge 1$  and  $\bar{u}_{I_k(T)}(c) \le \bar{u}_{\infty}(c) + \varepsilon$ . Now  $c|_{I_k(T)}$  is the desired treatment segment.

## S1.2.3 Results for linear and uniform induction of tolerance

We can now prove that for linear induction of tolerance, where  $\mu(c) = \mu_0 + kc$  for  $k \ge 0$  and  $\nu(c) = \nu_0 - mc$  for  $m \ge 0$ , a constant-dose treatment is optimal in the long run.

**Theorem 1.** For linear induction of tolerance, then for any treatment  $c : [0, \infty) \to [0, c_{\max}]$  which satisfies (A), we have that

$$\min_{\tilde{c}\in[0,c_{\max}]}\sigma(\tilde{c})\leq \bar{u}_{\infty}(c).$$

*Proof.* Let  $0 < \varepsilon \leq C$ , where C is chosen as in Lemma 3. By Lemma 4, we can find an  $\varepsilon$ -stable treatment segment  $c|_I$  so that  $|I| \geq 1$  and  $\bar{u}_I(c) \leq \bar{u}_\infty(c) + \varepsilon$ . By Lemma 3, the equilibrium growth rate  $\rho = \sigma(\bar{\lambda}_0(I), \lambda_1, \bar{\mu}(I), \bar{\nu}(I))$  of the constant-parameter model  $M(\bar{\lambda}_0(I), \lambda_1, \bar{\mu}(I), \bar{\nu}(I))$  satisfies  $\rho \leq \bar{u}_I(c) + D\varepsilon$ , where the constant D > 0 is independent of  $\varepsilon$ . Therefore,

$$\rho \le \bar{u}_I(c) + D\varepsilon \le \bar{u}_\infty(c) + (D+1)\varepsilon.$$

Let  $\bar{c}(I) := \frac{1}{|I|} \int_{I} c(t) dt$  denote the average dose over I. Since  $\mu(c)$  and  $\nu(c)$  are linear in c,  $\mu(\bar{c}(I)) = \bar{\mu}(I)$  and  $\nu(\bar{c}(I)) = \bar{\nu}(I)$ . Furthermore, since  $\lambda_0$  is convex,  $\lambda_0(\bar{c}(I)) \leq \bar{\lambda}_0(I)$  by Jensen's inequality. Then, by Lemma 1, we have that  $\sigma(\bar{c}(I)) \leq \rho$ , where  $\sigma(c)$  denotes the equilibrium growth rate under the constant-parameter model  $M(\lambda_0(c), \lambda_1, \mu(c), \nu(c))$ . We can conclude that

$$\min_{\tilde{c} \in [0, c_{\max}]} \sigma(\tilde{c}) \le \sigma(\bar{c}(I)) \le \bar{u}_{\infty} + (D+1)\varepsilon.$$

By sending  $\varepsilon \to 0$  in the right-hand side, we obtain the desired result.

We can also prove that for uniformly induced tolerance, where  $\mu(0) = \mu_0$ ,  $\mu(c) = \mu_{\text{max}}$  for c > 0 and  $\nu(0) = \nu_0$ ,  $\nu(c) = \nu_{\text{min}}$  for c > 0, an arbitrarily fast pulsed schedule alternating between the maximum dose  $c_{\text{max}}$  and no dose is optimal.

**Theorem 2.** For uniform induction of tolerance, then for any treatment  $c : [0, \infty) \to [0, c_{\max}]$  which satisfies (A), we have that

$$\min_{\varphi \in [0,1]} \sigma(c_{\max}, \varphi) \le \bar{u}_{\infty}(c).$$

*Proof.* Let  $0 < \varepsilon \leq C$ , where C is chosen as in Lemma 3. Like in the proof of Theorem 1, we can find an  $\varepsilon$ -stable treatment segment  $c|_I$  so that the constant-parameter model  $M(\bar{\lambda}_0(I), \lambda_1, \bar{\mu}(I), \bar{\nu}(I))$  has equilibrium growth rate  $\rho \leq \bar{u}_{\infty} + (D+1)\varepsilon$ . Now set  $S := \{t \in I : c(t) > 0\}$  and note that

$$\bar{\mu}(I) = \frac{1}{|I|} \int_{I} \mu(c) dc = \frac{1}{|I|} \left( \int_{S} \mu(c) dc + \int_{I \setminus S} \mu(c) dx \right) = \frac{|S|}{|I|} \mu_{\max} + \frac{|I \setminus S|}{|I|} \mu_{0}.$$

Similar calculations hold for  $\bar{\nu}$ . Therefore, there exists  $\varphi \in [0, 1]$  so that  $\bar{\mu}(I) = \varphi \mu_{\max} + (1 - \varphi)\mu_0$  and  $\bar{\nu}(I) = \varphi \nu_{\min} + (1 - \varphi)\nu_0$ . We also have that

$$\bar{\lambda}_{0}(I) = \frac{1}{|I|} \left( \int_{S} \lambda_{0}(c) dc + \int_{I \setminus S} \lambda_{0}(c) dx \right) \\
\geq \frac{|S|}{|I|} \lambda_{0}(c_{\max}) + \frac{|I \setminus S|}{|I|} \lambda_{0} \\
= \varphi \lambda_{0}(c_{\max}) + (1 - \varphi) \lambda_{0}.$$
(32)



Figure 9: Potential shapes of the function P(x) depending on whether  $\bar{\alpha} > 0$  or  $\bar{\alpha} < 0$ .

Recall from Section 4.7 that  $\sigma(c,\varphi)$  denotes the equilibrium growth rate of the constantparameter model  $M(\bar{\lambda}_0(c,\varphi),\lambda_1,\bar{\mu}(c,\varphi),\bar{\nu}(c,\varphi))$ , where  $\bar{\lambda}_0(c,\varphi) = \varphi \lambda_0(c) + (1-\varphi)\lambda_0$ ,  $\bar{\mu}(c,\varphi) = \varphi \mu(c) + (1-\varphi)\mu_0$  and  $\bar{\nu}(c,\varphi) = \varphi \nu(c) + (1-\varphi)\nu_0$ . Now, by (32) and Lemma 1,

$$\sigma(c_{\max},\varphi) \leq \rho_{s}$$

from which it follows that

$$\min_{\varphi \in [0,1]} \sigma(c_{\max}, \varphi) \le \bar{u}_{\infty} + (D+1)\varepsilon.$$

By sending  $\varepsilon \to 0$  in the right-hand side, we obtain the desired result.

## S1.3 Completion of the proof of Lemma 3

Here, we complete the proof of Lemma 3. We want to show that there exist constants  $C_2, C_3 > 0$  so that if  $\varepsilon \leq C_2$ , then

$$|g - \bar{f}_0| \le C_3 \varepsilon,$$

where the  $C_2$  and  $C_3$  only depend on  $\lambda_0$ ,  $\lambda_1$ ,  $\mu_0$ ,  $\mu_{\max}$ ,  $\nu_0$  and  $\nu_{\min}$ . Recall that  $P(x) = \bar{\alpha}x^2 + \bar{\beta}x + \bar{\nu}$ ,  $\bar{f}_0$  is the unique root of P in [0, 1], and  $g \in [0, 1]$  satisfies  $|P(g)| \leq C_1 \varepsilon$ .

For the case  $\bar{\alpha} = 0$ , P(x) is linear in x and the proof is straightforward. If  $\bar{\alpha} \neq 0$ , Figure 9 shows the four possible scenarios, depending on the sign of  $\bar{\alpha}$  and whether the axis of symmetry for P falls within [0,1]. In all cases, P is locally strictly decreasing at  $\bar{f}_0$ and the preimage  $P^{-1}([-C_1\varepsilon, C_1\varepsilon])$  is an interval  $[x_0, x_1]$  containing g and  $\bar{f}_0$ , assuming  $\varepsilon$  is sufficiently small that  $C_1\varepsilon \leq \bar{\nu}$ . Now assume that  $\bar{\alpha} < 0$ . Then, there are two solutions to P(x) = 0 and  $\bar{f}_0$  is the larger solution (Figure 9). Therefore, since  $\bar{\alpha} < 0$ ,

$$\bar{f}_0 = \frac{-\bar{\beta} - \sqrt{(\bar{\beta})^2 - 4\bar{\alpha}\bar{\nu}}}{2\bar{\alpha}},\tag{33}$$

and the endpoints  $x_0, x_1$  are given by

$$\begin{cases} x_0 \\ x_1 \end{cases} = \frac{-\bar{\beta} - \sqrt{(\bar{\beta})^2 - 4\bar{\alpha}(\bar{\nu} \mp C_1 \varepsilon)}}{2\bar{\alpha}}.$$

Consider first the left endpoint  $x_0$ , for which  $x_0 < \overline{f}_0$  and  $P(x_0) = C_1 \varepsilon$ . Note that

$$\sqrt{(\bar{\beta})^2 - 4\bar{\alpha}(\bar{\nu} - C_1\varepsilon)} = \sqrt{(\bar{\beta})^2 - 4\bar{\alpha}\bar{\nu}}\sqrt{1 - \frac{4|\bar{\alpha}|C_1}{\sqrt{(\bar{\beta})^2 - 4\bar{\alpha}\bar{\nu}}}\varepsilon},$$

where we use that  $(\bar{\beta})^2 - 4\bar{\alpha}\bar{\nu} > 0$  since  $\bar{\alpha} < 0, \bar{\nu} > 0$  and that  $\bar{\alpha} = -|\bar{\alpha}|$ . We can now use the inequality  $\sqrt{1-x} \ge 1-x$  for  $0 \le x \le 1$  to say that for  $\varepsilon \le \sqrt{(\bar{\beta})^2 - 4\bar{\alpha}\bar{\nu}}/(4|\bar{\alpha}|C_1)$ ,

$$\sqrt{1 - \frac{4|\bar{\alpha}|C_1}{\sqrt{(\bar{\beta})^2 - 4\bar{\alpha}\bar{\nu}}}}\varepsilon \ge 1 - \frac{4|\bar{\alpha}|C_1}{\sqrt{(\bar{\beta})^2 - 4\bar{\alpha}\bar{\nu}}}\varepsilon,$$

which implies since  $\bar{\alpha} < 0$ ,

$$\begin{split} \bar{f}_0 &- x_0 \\ &= \bar{f}_0 - \frac{-\bar{\beta} - \sqrt{(\bar{\beta})^2 - 4\bar{\alpha}(\bar{\nu} - C_1\varepsilon)}}{2\bar{\alpha}} \\ &= \bar{f}_0 + \frac{\bar{\beta}}{2\bar{\alpha}} + \frac{\sqrt{(\bar{\beta})^2 - 4\bar{\alpha}\bar{\nu}}\sqrt{1 - \frac{4|\bar{\alpha}|C_1}{\sqrt{(\bar{\beta})^2 - 4\bar{\alpha}\bar{\nu}}}\varepsilon}}{2\bar{\alpha}} \\ &\leq \bar{f}_0 + \frac{\bar{\beta}}{2\bar{\alpha}} + \frac{\sqrt{(\bar{\beta})^2 - 4\bar{\alpha}\bar{\nu}}}{2\bar{\alpha}} - \frac{\sqrt{(\bar{\beta})^2 - 4\bar{\alpha}\bar{\nu}}}{2\bar{\alpha}} \cdot \frac{4|\bar{\alpha}|C_1}{\sqrt{(\bar{\beta})^2 - 4\bar{\alpha}\bar{\nu}}}\varepsilon \\ &\leq \bar{f}_0 + \frac{\bar{\beta}}{2\bar{\alpha}} + \frac{\sqrt{(\bar{\beta})^2 - 4\bar{\alpha}\bar{\nu}}}{2\bar{\alpha}} + 2C_1\varepsilon \\ &= 2C_1\varepsilon. \end{split}$$

where in the final step we use (33). For the right endpoint  $x_1$ , for which  $x_1 > \overline{f}_0$  and  $P(x_1) = -C_1 \varepsilon$ , we note similarly that

$$\sqrt{(\bar{\beta})^2 - 4\bar{\alpha}(\bar{\nu} + C_1\varepsilon)} = \sqrt{(\bar{\beta})^2 - 4\bar{\alpha}\bar{\nu}}\sqrt{1 + \frac{4|\bar{\alpha}|C_1}{\sqrt{(\bar{\beta})^2 - 4\bar{\alpha}\bar{\nu}}}\varepsilon}$$

We can now use the inequality  $\sqrt{1+x} \le 1+x$  for  $x \ge 0$  to say that

$$\sqrt{1 + \frac{4|\bar{\alpha}|C_1}{\sqrt{(\bar{\beta})^2 - 4\bar{\alpha}\bar{\nu}}}} \varepsilon \le 1 + \frac{4|\bar{\alpha}|C_1}{\sqrt{(\bar{\beta})^2 - 4\bar{\alpha}\bar{\nu}}} \varepsilon,$$

which implies since  $\bar{\alpha} < 0$ ,

$$\begin{aligned} x_1 &- f_0 \\ &= \frac{-\bar{\beta} - \sqrt{(\bar{\beta})^2 - 4\bar{\alpha}(\bar{\nu} + C_1\varepsilon)}}{2\bar{\alpha}} - \bar{f}_0 \\ &= -\frac{\bar{\beta}}{2\bar{\alpha}} - \frac{\sqrt{(\bar{\beta})^2 - 4\bar{\alpha}\bar{\nu}}\sqrt{1 + \frac{4|\bar{\alpha}|C_1}{\sqrt{(\bar{\beta})^2 - 4\bar{\alpha}\bar{\nu}}}\varepsilon}}{2\bar{\alpha}} - \bar{f}_0 \\ &\leq -\bar{f}_0 - \frac{\bar{\beta}}{2\bar{\alpha}} - \frac{\sqrt{(\bar{\beta})^2 - 4\bar{\alpha}\bar{\nu}}}{2\bar{\alpha}} + 2C_1\varepsilon \\ &= 2C_1\varepsilon. \end{aligned}$$

Since  $g \in [x_0, x_1]$ , we can now guarantee that for  $\varepsilon \leq \sqrt{(\bar{\beta})^2 - 4\bar{\alpha}\bar{\nu}}/(4|\bar{\alpha}|C_1)$ ,

$$|g - \bar{f}_0| \le 2C_1 \varepsilon.$$

The same statement applies to the case  $\bar{\alpha} > 0$ . We have therefore shown that there exist constants  $C_2, C_3 > 0$  so that if  $\varepsilon \leq C_2$ , then  $|g - \bar{f}_0| \leq C_3 \varepsilon$ . It remains to be shown that the constants  $C_2, C_3$  can be selected so that they only depend on  $\lambda_0, \lambda_1, \mu_0, \mu_{\max}, \nu_0$  and  $\nu_{\min}$ . For  $C_3$ , this is easy, since we can set  $C_3 := 2C_1$  and we know that  $C_1 = 1 + 3(\lambda_0 + \lambda_1) + (\mu_{\max} + \nu_0)$ . For  $C_2$ , note first that  $|\bar{\alpha}| \leq \lambda_0 + \lambda_1$  and note next that

$$(\bar{\beta})^2 - 4\bar{\alpha}\bar{\nu} = \left(\lambda_1 - \bar{\lambda}_0 + \bar{\mu} + \bar{\nu}\right)^2 - 4(\lambda_1 - \bar{\lambda}_0)\bar{\nu}.$$

Consider the polynomial  $Q(x) := (x + \bar{\mu} + \bar{\nu})^2 - 4x\bar{\nu}$ . This polynomial takes the smallest value at  $x = \bar{\nu} - \bar{\mu}$ , and the smallest value is  $4\bar{\mu}\bar{\nu} \ge 4\mu_0\nu_{\min}$ . Recalling that we also need  $C_1 \varepsilon \le \bar{\nu}$ , we set

$$C_2 := \frac{1}{1 + 3(\lambda_0 + \lambda_1) + (\mu_{\max} + \nu_0)} \min\left\{\frac{2\sqrt{\mu_0\nu_{\min}}}{\lambda_0 + \lambda_1}, \nu_{\min}\right\}.$$

Since  $C_1 = 1 + 3(\lambda_0 + \lambda_1) + (\mu_{\max} + \nu_0)$ , we have that

$$C_2 \leq \frac{1}{C_1} \min\left\{\frac{\sqrt{(\bar{\beta})^2 - 4\bar{\alpha}\bar{\nu}}}{4|\bar{\alpha}|}, \bar{\nu}\right\},\,$$

as desired.

## S1.4 Transient phase of the optimal treatment

#### S1.4.1 General case

Assume that at the start of treatment, the proportion of sensitive cells is  $\bar{f}_0(0)$ . The objective of our optimal control problem (17) is to minimize

$$\int_0^T u(c, f_0) dt, \tag{34}$$

where  $u(c, f_0) = (\lambda_1 - \lambda_0(c))f_0 + \lambda_1$  is the instantaneous tumor growth rate. Both for the case of linear and uniformly induced tolerance, there is an optimal long-run growth rate  $\sigma^*$  and an associated equilibrium proportion  $\bar{f}_0^*$ . Instead of minimizing (34), we can minimize

$$\int_0^T (u(c, f_0) - \sigma^*) dt,$$

and since the growth rate under the optimal policy is eventually  $\sigma^*$ , we have that

$$\int_0^T (u(c, f_0) - \sigma^*) dt = \int_0^\infty (u(c, f_0) - \sigma^*) dt,$$

given that T is sufficiently large. During the transient phase, we can assume that  $f_0(t)$  is strictly decreasing. The reason is that if there are two times  $t_1 < t_2$  such that  $f_0(t_1) = f_0(t_2)$ and  $\int_{t_1}^{t_2} (u(c, f_0) - \sigma^*) dt < 0$ , we can repeat the segment between  $t_1$  and  $t_2$  indefinitely to obtain a treatment with a long-run average growth rate less than  $\sigma^*$ , which is a contradiction. If  $\int_{t_1}^{t_2} (u(c, f_0) - \sigma^*) dt \ge 0$ , we can remove the segment between  $t_1$  and  $t_2$  without increasing the integral  $\int_0^{\infty} (u(c, f_0) - \sigma^*) dt$ . Assuming that  $f_0(t)$  is strictly decreasing, we can apply the following coordinate change:

$$\int_0^\infty (u(c(t), f_0(t)) - \sigma^*) dt = \int_{\bar{f}_0(0)}^{\bar{f}_0^*} \frac{u(c, f_0) - \sigma^*}{df_0/dt} df_0 = \int_{\bar{f}_0^*}^{\bar{f}_0(0)} \frac{u(c, f_0) - \sigma^*}{-df_0/dt} df_0.$$

To minimize this integral, we can for each fixed  $f_0$  minimize

$$\frac{u(c,f_0) - \sigma^*}{-f_0'}$$

with respect to c, or equivalently maximize

$$\frac{\sigma^* - u(c, f_0)}{-f_0'}$$

with respect to c. Since  $f_0(t)$  is strictly decreasing, we can apply the constraint that  $f'_0 < 0$ .

## S1.4.2 Linear induction of tolerance

For linear induction of tolerance, we wish to reformulate the condition  $f'_0 < 0$  in terms of c. By (11), we have that

$$f_0' = (\lambda_1 - \lambda_0(c)) f_0^2 - (\lambda_1 - \lambda_0(c) + \mu(c) + \nu(c)) f_0 + \nu(c),$$

which we can write explicitly as

$$\begin{aligned} f_0' &= \left(\lambda_1 - \lambda_0 + \Delta d_0 \frac{c}{c+1}\right) f_0^2 - \left(\lambda_1 - \lambda_0 + \Delta d_0 \frac{c}{c+1} + \mu_0 + kc + \nu_0 - mc\right) f_0 + \nu_0 - mc \\ &= \Delta d_0 f_0 (f_0 - 1) \frac{c}{c+1} + (mf_0 - kf_0 - m)c + ((\lambda_1 - \lambda_0)f_0 (f_0 - 1) - (\mu_0 + \nu_0)f_0 + \nu_0) \\ &= \frac{\Delta d_0 f_0 (f_0 - 1)c + (mf_0 - kf_0 - m)c(c+1) + ((\lambda_1 - \lambda_0)f_0 (f_0 - 1) - (\mu_0 + \nu_0)f_0 + \nu_0)(c+1)}{c+1} \end{aligned}$$

Note that

$$\begin{aligned} \Delta d_0 f_0(f_0 - 1)c + (mf_0 - kf_0 - m)c(c + 1) + ((\lambda_1 - \lambda_0)f_0(f_0 - 1) - (\mu_0 + \nu_0)f_0 + \nu_0)(c + 1) \\ &= (m(f_0 - 1) - kf_0)c^2 \\ &+ (m(f_0 - 1) - kf_0 + \Delta d_0 f_0(f_0 - 1) + (\lambda_1 - \lambda_0)f_0(f_0 - 1) - (\mu_0 + \nu_0)f_0 + \nu_0)c \\ &+ ((\lambda_1 - \lambda_0)f_0(f_0 - 1) - (\mu_0 + \nu_0)f_0 + \nu_0). \end{aligned}$$

If we now set

$$\begin{split} A &:= m(f_0 - 1) - kf_0, \\ B &:= \Delta d_0 f_0(f_0 - 1), \\ D &:= (\lambda_1 - \lambda_0) f_0(f_0 - 1) - (\mu_0 + \nu_0) f_0 + \nu_0, \end{split}$$

we can write

$$f_0' = \frac{Ac^2 + (A + B + D)c + D}{c+1}.$$

The equation  $Ac^2 + (A + B + D)c + D = 0$  has solutions

$$c = \frac{-(A+B+D) \pm \sqrt{(A+B+D)^2 - 4AD}}{2A}.$$

Since  $k, m \ge 0$ , with either  $k \ne 0$  or  $m \ne 0$ , and  $0 < f_0 < 1$ , we have A < 0, and for  $f_0 \le \overline{f_0}(0)$ , we have  $D \ge 0$ . This implies that  $AD \le 0$ . If D = 0, we get that  $f'_0 < 0$  if and only if  $Ac^2 + (A + B)c < 0$ , which is equivalent to c > -(A + B)/A with the restriction that  $c \ge 0$ . In this case, we take  $c_{\min}(f_0) := -(A+B)/A$ . If D > 0, then  $Ac^2 + (A+B+D)c+D = 0$  has one positive and one negative solution. Let  $c_{\min}(f_0)$  denote the positive solution. Then with the restriction that  $c \ge 0$ , the condition  $f'_0 < 0$  is equivalent to  $c > c_{\min}(f_0)$ .

## S1.4.3 Uniform induction of tolerance

Here, we want to show that under uniform induction of tolerance, the maximum dose  $c_{\max}$  is optimal during the transient phase. First, we note that if the treatment is started at  $\bar{f}_0(0)$ , we can exclude the possibility that c = 0 is optimal since this will lead to  $f'_0 \ge 0$ . It therefore suffices to consider doses c > 0. Using (11) and (14), we can explicitly write

$$\frac{\sigma^* - u(c, f_0)}{-f'_0} = \frac{\sigma^* - (\lambda_0(c) - \lambda_1)f_0 - \lambda_1}{\left(\lambda_0(c) - \lambda_1\right)f_0^2 + \left(\lambda_1 - \lambda_0(c) + \mu(c) + \nu(c)\right)f_0 - \nu(c)}$$
$$= \frac{\lambda_0(c)f_0 + \left(\lambda_1(1 - f_0) - \sigma^*\right)}{\lambda_0(c)f_0(1 - f_0) + \left(\nu(c)(1 - f_0) - \mu(c)f_0 - \lambda_1f_0(1 - f_0)\right)}$$

In this case, we have  $\mu(c) = \mu_{\text{max}}$  and  $\nu(c) = \nu_{\text{min}}$  for c > 0. Therefore, if we set

$$\begin{split} a &:= f_0, \\ b &:= \lambda_1 (1 - f_0) - \sigma^*, \\ d &:= f_0 (1 - f_0), \\ e &:= \nu_{\min} (1 - f_0) - \mu_{\max} f_0 - \lambda_1 f_0 (1 - f_0), \end{split}$$

we can write for c > 0:

$$\frac{\sigma^* - u(c, f_0)}{-f'_0} = \frac{a\lambda_0(c) + b}{d\lambda_0(c) + e}.$$
(35)

This leads us to studying the function

$$f(x) := \frac{ax+b}{dx+e}.$$

Since  $f'(x) = (ae-bd)/(dx+e)^2$ , this function is either strictly increasing, strictly decreasing or constant depending on the sign of ae - bd. We wish to show that for any  $f_0 > \bar{f}_0^*$ , we have ae - bd < 0, meaning that f(x) is strictly decreasing in x. This in turns means that the largest value of (35) is attained when  $\lambda_0(c)$  is smallest, which occurs at  $c = c_{\text{max}}$ .

To analyze ae - bd, we begin by computing:

$$\begin{aligned} ae - bd &= f_0 \left( \nu_{\min} (1 - f_0) - \mu_{\max} f_0 - \lambda_1 f_0 (1 - f_0) \right) - f_0 (1 - f_0) \left( \lambda_1 (1 - f_0) - \sigma^* \right) \\ &= \nu_{\min} f_0 (1 - f_0) - \mu_{\max} f_0^2 - \lambda_1 f_0^2 (1 - f_0) - \lambda_1 f_0 (1 - f_0)^2 + \sigma^* f_0 (1 - f_0) \\ &= \nu_{\min} f_0 (1 - f_0) - \mu_{\max} f_0^2 - \lambda_1 f_0 (1 - f_0) + \sigma^* f_0 (1 - f_0) \\ &= \left( \sigma^* - \lambda_1 + \nu_{\min} \right) f_0 (1 - f_0) - \mu_{\max} f_0^2. \end{aligned}$$

If  $\sigma^* - \lambda_1 + \nu_{\min} \leq 0$ , then  $ae - bd \leq -\mu_{\max}f_0^2 < 0$  whenever  $f_0 > \bar{f}_0^*$  and we are done. For the case  $\sigma^* - \lambda_1 + \nu_{\min} > 0$ , we define

$$m := \sigma^* - \lambda_1 + \nu_{\min},$$
$$n := \mu_{\max}$$

with m, n > 0, and we further define the function

$$g(x) := mx(1-x) - nx^2 = -(m+n)x^2 + mx.$$

Note that g is a second-degree polynomial with roots x = 0 and  $x = \frac{m}{m+n}$ . Since m + n > 0, we know that g(x) > 0 for  $x \in [0, m/(m+n))$  and g(x) < 0 for  $x \in (m/(m+n), 1]$ . If we are able to show that

$$\bar{f}_0^* \ge \frac{m}{m+n} = \frac{\sigma^* - \lambda_1 + \nu_{\min}}{\sigma^* - \lambda_1 + \mu_{\max} + \nu_{\min}},\tag{36}$$

it will follow that for any  $f_0 > \overline{f}_0^*$ , we have ae - bd < 0 as desired.

To establish (36), note first that by Lemma 2,

$$\frac{\sigma^* - \lambda_1 + \nu_{\min}}{\sigma^* - \lambda_1 + \mu_{\max} + \nu_{\min}} = \frac{(\bar{\lambda}_0(c_{\max}, \varphi^*) - \lambda_1)\bar{f}_0^* + \nu_{\min}}{(\bar{\lambda}_0(c_{\max}, \varphi^*) - \lambda_1)\bar{f}_0^* + \mu_{\max} + \nu_{\min}},$$

where

$$\bar{\lambda}_0(c,\varphi) = \varphi \lambda_0(c) + (1-\varphi)\lambda_0,$$

as defined in Section 4.7. Next note that by (20),

$$\begin{aligned} &(\bar{\lambda}_0(c_{\max},\varphi^*) - \lambda_1)((\bar{f}_0^*)^2 - \bar{f}_0^*) + \bar{\mu}(c_{\max},\varphi^*)\bar{f}_0^* - \bar{\nu}(c_{\max},\varphi^*)(1 - \bar{f}_0^*) \\ &= \left(\bar{\lambda}_0(c_{\max},\varphi^*) - \lambda_1\right)(\bar{f}_0^*)^2 - \left(\bar{\lambda}_0(c_{\max},\varphi^*) - \lambda_1 - \bar{\mu}(c_{\max},\varphi^*) - \bar{\nu}(c_{\max},\varphi^*)\right)\bar{f}_0^* - \bar{\nu}(c_{\max},\varphi^*) \\ &= 0. \end{aligned}$$

Since

$$\bar{\mu}(c_{\max},\varphi^*) = \varphi^* \mu_{\max} + (1-\varphi^*)\mu_0 = \mu_{\max} + (1-\varphi^*)(\mu_0 - \mu_{\max}),\\ \bar{\nu}(c_{\max},\varphi^*) = \varphi^* \nu_{\min} + (1-\varphi^*)\nu_0 = \nu_{\min} + (1-\varphi^*)(\nu_0 - \nu_{\min}),$$

it follows that

$$\begin{aligned} &(\bar{\lambda}_0(c_{\max},\varphi^*)-\lambda_1)((\bar{f}_0^*)^2-\bar{f}_0^*)+\mu_{\max}\bar{f}_0^*-\nu_{\min}(1-\bar{f}_0^*)\\ &=(1-\varphi^*)(\mu_{\max}-\mu_0)\bar{f}_0^*+(1-\varphi^*)(\nu_0-\nu_{\min})(1-\bar{f}_0^*)\\ &\ge 0, \end{aligned}$$

which implies that

$$\frac{(\lambda_0(c_{\max},\varphi^*)-\lambda_1)f_0^*+\nu_{\min}}{(\bar{\lambda}_0(c_{\max},\varphi^*)-\lambda_1)\bar{f}_0^*+\mu_{\max}+\nu_{\min}} \leq \bar{f}_0^*.$$

This concludes the proof.

#### S1.5 Pulsed schedules

#### S1.5.1 More rapid pulses give at least as low long-run growth rate

We show that any pulsed treatment  $T_1 := (c, t_{\text{cycle}}, \varphi_1)$  can be modified to get an equally good or better pulsed treatment  $T_2 := (c, t_{\text{cycle}}/2, \varphi_2)$ . We assume  $T_1$  is started so that  $f_0$ is already in equilibrium, i.e.,  $f_0$  is a periodic function of time with period  $t_{\text{cycle}}$ . Assume the treatment is started in such a way that the drug is applied from time t = 0 to time  $t = \varphi_1 t_{\text{cycle}}$  and then not applied from time  $t = \varphi_1 t_{\text{cycle}}$  to time  $t_{\text{cycle}}$ . Then,  $f_0$  starts at some  $y_1$  at time t = 0, changes monotonically to  $y_2$  over  $\varphi_1 t_{\text{cycle}}$  units of time, and then changes monotonically back to  $y_1$  over  $(1 - \varphi_1)t_{\text{cycle}}$  units of time. There exists some  $y_m$ between  $y_1$  and  $y_2$  such that the combined time it takes for  $f_0$  to go from  $y_1$  to  $y_m$  and from  $y_m$  to  $y_1$  is exactly  $t_{\text{cycle}}/2$ . Then the combined time for  $f_0$  to go from  $y_m$  to  $y_2$  and from  $y_2$  to  $y_m$  is exactly  $t_{\text{cycle}}/2$  as well. Let  $t_1$  and  $t_2$   $(t_1, t_2 < t_{\text{cycle}})$  be times in the first period where  $f_0 = y_m$ . Since  $T_1$  is started in equilibrium, long-run average growth rate is simply the average growth rate over the time-interval  $[0, t_{cycle}]$ , which is in turn the average of the growth rates over the sets  $[0, t_1] \cup [t_2, t_{cycle}]$  and  $[t_1, t_2]$ . The average growth rate over one of these sets must be at least as good as the long-run growth rate. If the former is better then we can simply choose  $T_2$  to be the treatment where we apply dose c for time  $t_1$  and then don't apply the dose from time  $t_2$ , that is,  $T_2 = (c, t_{\text{cycle}}/2, 2t_1/t_{\text{cycle}})$ . If the latter is better we can similarly chose  $T_2$  to be the treatment where we apply the drug for time  $\varphi t_{\text{cycle}} - t_1$ and do not apply the drug for time  $t_2 - \varphi t_{\text{cycle}}$ , that is  $T_2 = (c, t_{\text{cycle}}/2, 2\varphi - 2t_1/t_{\text{cycle}})$ .

# S1.5.2 Once pulses are rapid enough, the long-run growth rate is insensitive to the cycle length

Here we show that if the treatment pulses are fast enough for the graph of  $f_0$  to be approximately linear during both the on-drug and off-drug phase of each treatment cycle, then the cycle duration does not matter as long as the average  $f_0$  is the same.

Assume we have two different pulsed dosing schedules  $T_1 = (c, t_{\text{cycle},1}, \varphi)$  and  $T_2 = (c, t_{\text{cycle},2}, \varphi)$  that are applied in a scenario where they have the same average value of  $f_0$ 

and in which  $f_0$  has reached equilibrium, meaning that  $f_0$  is periodic. Additionally assume that  $f_0$  behaves linearly during both the on-drug and off-drug phase in each case. Since the lines are approximations of the true model, we should assume the corresponding line segments have the same slope. Let  $y_1$  and  $y_2$  be the lowest and largest values of  $f_0$  under schedule  $T_1$ , and similarly, let  $y_3$  and  $y_4$  be the smallest and largest values under schedule  $T_2$ . Let  $[t_1, t_3]$  be a period of the treatment with schedule  $T_1$  such that the drug is administered during the interval  $[t_1, t_2]$  and is not administered during the interval  $[t_2, t_3]$ . Under the above assumptions, the average growth rate using schedule  $T_1$  is

$$\varphi \frac{\int_{t_1}^{t_2} ((\lambda_0(c) - \lambda_1) f_0 + \lambda_1) dt}{t_2 - t_1} + (1 - \varphi) \frac{\int_{t_2}^{t_3} ((\lambda_0(0) - \lambda_1) f_0 + \lambda_1) dt}{t_3 - t_2}$$

but since  $f_0$  is approximately linear on these intervals this is equal to

$$\varphi \left( (\lambda_0(c) - \lambda_1) \frac{(t_2 - t_1)y_m}{t_2 - t_1} + \lambda_1 \right) + (1 - \varphi) \left( (\lambda_0(0) - \lambda_1) \frac{(t_3 - t_2)y_m}{t_3 - t_2} + \lambda_1 \right)$$
  
=  $\varphi (\lambda_0(c) - \lambda_1) y_m + (1 - \varphi) (\lambda_0(0) - \lambda_1) y_m + \lambda_1,$ 

which would be the same if we did the same calculations for  $T_2$ .

## S1.6 Implementation of Russo et al. [18] model

#### S1.6.1 Model and parametrization

In Russo et al. [18], the authors use their experimental data to parametrize a mathematical model involving two cell types, sensitive and tolerant. The drug effect on the sensitive cell death rate  $d_0$  is modeled using a function of the form

$$d_0(c) = d_0 + (d_{\max} - d_0)(1 - \exp(-ac)) = d_0 + \Delta d_0(1 - \exp(-ac)),$$

where c is the drug dose measured in M. Under this model, the dose which has half the maximal effect on the sensitive cell death rate is given by  $EC_{50}^d = \log(2)/a$ . If we measure the drug dose as a proportion of the  $EC_{50}^d$  dose, we can rewrite the above function as

$$d_0(c) = d_0 + \Delta d_0 (1 - \exp(-c\log(2))).$$
(37)

We note that this version of  $d_0(c)$  is concave in c, same as the functional form we assume in Section 4.2.

For the WiDr cell line, Russo et al. infer that the transition rate  $\mu(c)$  from sensitivity to tolerance is given by the linear function

$$\mu(c) = k'c,$$

where c is the drug dose measured in  $\mu M$ . If we again measure the drug dose as a proportion of the  $\text{EC}_{50}^d$  dose and define  $k := k' \text{EC}_{50}$ , we can rewrite this function as

$$\mu(c) = kc$$

With this modeling setup, the authors in [18] use their experimental data to derive the parameter estimates  $\lambda_0 = b_0 - d_0 = 0.048$ ,  $a = 2.91495 \cdot 10^6$ ,  $\Delta d_0 = 1.095$ ,  $\lambda_1 = -0.073$  and k' = 136935 for the WiDr B7 clone. For these estimates, the EC<sup>d</sup><sub>50</sub> dose is given by

$$\mathrm{EC}_{50}^{d} = \frac{\log(2)}{2.91495 \cdot 10^{6}} = 2.3779 \cdot 10^{-7} \ M,$$

and the rescaled slope k is given by

$$k = 136935 \cdot \text{EC}_{50}^d = 0.03256$$

## S1.6.2 Implementation of forward-backward sweep method

To solve the optimal control problem (17) using the drug effect function in (37), we can apply the forward-backward sweep method as laid out in Section S1.1 with one modification. In the fifth step, we have to solve  $\partial \mathcal{H}/\partial c = 0$ . We again have that

$$\frac{\partial \mathcal{H}}{\partial c} = (f_0 - \gamma f_0^2 + \gamma f_0) \frac{\partial \lambda_0}{\partial c} - \gamma f_0 \frac{\partial \mu}{\partial c} + \gamma (1 - f_0) \frac{\partial \nu}{\partial c},$$

but we must modify our calculation of  $\partial \lambda_0 / \partial c$ . In this case, we have

$$\lambda_0(c) = \lambda_0 - \Delta d_0 (1 - \exp(-c \log(2))),$$

which implies that

$$\frac{\partial \lambda_0}{\partial c} = -\log(2)(\Delta d_0)\exp(-c\log(2)),$$

and we obtain the equation

$$-\log(2)(\Delta d_0)\exp(-c\log(2))(f_0 - \gamma f_0^2 + \gamma f_0) - \gamma f_0 k = 0.$$

If we now set

$$a(f_0, \gamma) := \log(2)(\Delta d_0) f_0(\gamma f_0 - 1 - \gamma), b(f_0, \gamma) := -\gamma f_0 k,$$

we obtain

$$\exp(-c\log(2)) = -\frac{b}{a},$$

which yields  $c = -\log(-b/a)/\log(2)$ . This is the solution we use in the fifth step.

#### S1.6.3 Natural transitions between phenotypes

In Russo et al. [18], the authors assume no transitions between sensitive and tolerant cells in the absence of drug,  $\mu_0 =$  and  $\nu_0 = 0$ . For the WiDr cell line (clone B7), their point estimate for the proportion of sensitive cells at the start of treatment is 0.992, which would indicate natural transitions. However, the proportion is indistinguishable from zero when statistical uncertainty is taken into account. The authors point out that transitions from tolerance to sensitivity may occur even in the presence of drug, but that these transitions would effectively contribute to the death rate of tolerant cells. Overall, it is uncertain whether cells transition between sensitivity and tolerance in the absence of drug. To be consistent with our modeling framework, we assume these transitions do occur, so that they lead to an equilibrium proportion  $\bar{f}_0(0) = 0.992$  of sensitivite cells in the absence of drug. This leads us to take  $\mu_0 = \nu_0 = 0.001$ , which is still consistent with Russo et al.'s finding that drug tolerance is primarily induced by the drug. A summary of the parameter values used for the analysis in Section 2.3 of the main text is given in Table 2.

Parameter	$\lambda_0$	$\Delta d_0$	$\lambda_1$	$\mu_0$	$ u_0 $	k
Value	0.048	1.095	-0.073	0.001	0.001	0.03256

Table 2: Parameter values used in Section 2.3.



Figure S1: When the treatment horizon in Figure 2 is extended, the period during which the constant dose  $c^*$  is applied becomes extended.